var title_f16_52_17216="E-test MIC determination";
var content_f16_52_17216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Antimicrobial gradient method (E-test)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An antibiotic-impregnated strip is incubated overnight on a Mueller-Hinton plate containing a standard bacterial inoculum: The&nbsp;minimum inhibitory concentration&nbsp;is determined by reading where the elliptical zone of clearing intersects with the strip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17216=[""].join("\n");
var outline_f16_52_17216=null;
var title_f16_52_17217="Patient information: Varicocele (The Basics)";
var content_f16_52_17217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17164\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/16/12544\">",
"         Varicocele",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/29/17873\">",
"         Patient information: Hydrocele (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Varicocele (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/varicocele-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6662695\">",
"      <span class=\"h1\">",
"       What is a varicocele?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A varicocele is a group of swollen veins inside the scrotum. The scrotum is the skin sac that holds the testicles, the 2 ball-shaped organs that hang between a man&rsquo;s legs. Boys and men can get varicoceles at any age (",
"      <a class=\"graphic graphic_figure graphicRef70115 \" href=\"UTD.htm?12/16/12544\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662710\">",
"      <span class=\"h1\">",
"       What are the symptoms of a varicocele?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A varicocele does not always cause symptoms. When it does, the symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain &ndash; It might hurt when you stand up and feel better when you lie down.",
"       </li>",
"       <li>",
"        Feeling as though 1 testicle is heavier than the other",
"       </li>",
"       <li>",
"        Swelling in 1 testicle",
"       </li>",
"       <li>",
"        Testicles that look different in size",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some men with a varicocele have trouble getting a woman pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662725\">",
"      <span class=\"h1\">",
"       Is there a test for a varicocele?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not usually. If you have a swelling that feels like a varicocele, your doctor or nurse will probably be able to tell what it is by doing an exam and asking about your symptoms.",
"     </p>",
"     <p>",
"      If the doctor or nurse is not sure what you have, he or she might order an ultrasound test. This test uses sound waves to create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662740\">",
"      <span class=\"h1\">",
"       How is a varicocele treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most varicoceles do not need treatment. When they do, treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain medicines, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin), if the varicocele causes discomfort",
"       </li>",
"       <li>",
"        Wearing tighter underwear or an athletic supporter (jock strap) to support the scrotum &nbsp;",
"       </li>",
"       <li>",
"        Surgery to stop blood from flowing into the swollen veins",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662755\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/29/17873?source=see_link\">",
"       Patient information: Hydrocele (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/52/17217?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17164 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17217=[""].join("\n");
var outline_f16_52_17217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662695\">",
"      What is a varicocele?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662710\">",
"      What are the symptoms of a varicocele?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662725\">",
"      Is there a test for a varicocele?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662740\">",
"      How is a varicocele treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662755\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17164\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/16/12544\">",
"      Varicocele",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/29/17873?source=related_link\">",
"      Patient information: Hydrocele (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_52_17218="Patient information: Miscarriage (The Basics)";
var content_f16_52_17218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15610\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/62/20450\">",
"         Patient information: Repeated miscarriage (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/17/36113\">",
"         Patient information: Threatened miscarriage (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/8/28803\">",
"         Patient information: Miscarriage (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Miscarriage (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/miscarriage-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H564846684\">",
"      <span class=\"h1\">",
"       What is miscarriage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Miscarriage is when a pregnancy ends before a woman has been pregnant for 20 weeks. (A normal pregnancy lasts about 40 weeks.) The uterus, also called the &ldquo;womb,&rdquo; is the part of a woman&rsquo;s body where a baby grows (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). A &ldquo;fetus&rdquo; is what a baby is called while it is growing inside you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H564846691\">",
"      <span class=\"h1\">",
"       What causes miscarriage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different problems can cause miscarriage. It can happen when:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The fetus begins to develop but then stops growing, often because it has genetic problems",
"       </li>",
"       <li>",
"        The mother has certain medical problems, such as poorly controlled diabetes, or problems with the shape of her uterus",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H564846698\">",
"      <span class=\"h1\">",
"       What are the symptoms of miscarriage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms are bleeding from the vagina and belly pain or cramping. See your doctor or nurse right away if you are pregnant and have these symptoms. If you are not sure if you are pregnant, take a urine pregnancy test to be sure.",
"     </p>",
"     <p>",
"      You should also see your doctor or nurse if you are pregnant and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have a fever (101&deg;F [38.3&deg;C] or higher)",
"       </li>",
"       <li>",
"        Anything solid comes out of your vagina",
"       </li>",
"       <li>",
"        Thick fluid that smells bad comes out of your vagina",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you cannot get in touch with your doctor or nurse, or if you have heavy bleeding (soaking a sanitary pad in 1 to 2 hours), go to the emergency room.",
"     </p>",
"     <p>",
"      These symptoms do not always mean that you are having a miscarriage. Your doctor can help figure out if anything is wrong.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H564846705\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might be able to tell if you have had a miscarriage just by asking you questions and doing a pelvic exam. He or she might also look at your uterus using an ultrasound, a machine that uses sound waves to create a picture of the inside of your body. That way, the doctor can look at the fetus and check whether it has a heartbeat. If your fetus has a heartbeat, you have not had a miscarriage. Your doctor can tell you if you are likely to have one. You might also need a blood test and then another blood test several days later to check on your pregnancy.",
"     </p>",
"     <p>",
"      If you have a negative blood type (such as &ldquo;O negative&rdquo;), you might need a special injection to help prevent problems in future pregnancies. If you don&rsquo;t know your blood type, ask your doctor or nurse to check it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H564846712\">",
"      <span class=\"h1\">",
"       How is miscarriage treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You cannot stop a miscarriage that has already started. If you have had a miscarriage, the fetus and the extra fluid in your uterus need to leave your body. Your doctor might want you just to wait and let it exit through your vagina by itself. If this is not an option, your doctor might treat you with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicine to help your uterus get rid of what was inside it, or",
"       </li>",
"       <li>",
"        Surgery to remove the contents of your uterus leftover from pregnancy",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H564846719\">",
"      <span class=\"h1\">",
"       Can I prevent a miscarriage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no way to make sure that you will not have a miscarriage. But you can reduce your chances of having one by avoiding cigarettes, alcohol, caffeine, and any injury to your belly. Having a fever or some kinds of infections puts you at risk for miscarriage, so you should also talk to your doctor about how to avoid getting sick.",
"     </p>",
"     <p>",
"      Some of the tests women have to check on the fetus during pregnancy can &mdash; in rare cases &mdash; cause miscarriages. If your doctor suggests testing your fetus, ask whether the test could cause a miscarriage. Also, some medicines or other treatments can be harmful to a fetus. Before you take any medicine (herbal, over-the-counter, or prescription) or have a medical treatment or X-ray, ask your doctor or nurse whether it could hurt your fetus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H564846726\">",
"      <span class=\"h1\">",
"       What do I do after a miscarriage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After you have had a miscarriage, you should not have sex or put anything in your vagina for 2 weeks. You can start using birth control again right after having a miscarriage.",
"     </p>",
"     <p>",
"      It is normal to feel sad or anxious after you have a miscarriage. But some women become truly depressed. If you think you might be depressed, mention it to your doctor. There are treatments and coping strategies that can help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H564846733\">",
"      <span class=\"h1\">",
"       Will I be able to have a normal pregnancy after a miscarriage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Most women who have a miscarriage go on to have healthy pregnancies. Still, women who have had a miscarriage are more likely than those who have not to have other miscarriages.",
"     </p>",
"     <p>",
"      Your doctor might suggest that you wait 2 or 3 months before trying to become pregnant again. If you have 3 or more miscarriages, your doctor might want to run some tests to try to figure out the reason.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H564846740\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=see_link\">",
"       Patient information: Threatened miscarriage (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/62/20450?source=see_link\">",
"       Patient information: Repeated miscarriage (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=see_link\">",
"       Patient information: Miscarriage (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/52/17218?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15610 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17218=[""].join("\n");
var outline_f16_52_17218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564846684\">",
"      What is miscarriage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564846691\">",
"      What causes miscarriage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564846698\">",
"      What are the symptoms of miscarriage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564846705\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564846712\">",
"      How is miscarriage treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564846719\">",
"      Can I prevent a miscarriage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564846726\">",
"      What do I do after a miscarriage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564846733\">",
"      Will I be able to have a normal pregnancy after a miscarriage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564846740\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15610\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=related_link\">",
"      Patient information: Miscarriage (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/62/20450?source=related_link\">",
"      Patient information: Repeated miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=related_link\">",
"      Patient information: Threatened miscarriage (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_52_17219="Penile scabies";
var content_f16_52_17219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penile scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small erythemetous papule is visible on the glans penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17219=[""].join("\n");
var outline_f16_52_17219=null;
var title_f16_52_17220="Nephrology pattern 5 answer";
var content_f16_52_17220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 5 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eosinophils in acute interstitial nephritis. Light micrograph with hematoxylin and eosin stain of acute interstitial nephritis showing diffuse interstitial infiltrate with many red-staining eosinophils. An uninvolved glomerulus is on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17220=[""].join("\n");
var outline_f16_52_17220=null;
var title_f16_52_17221="Doxylamine: Drug information";
var content_f16_52_17221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxylamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/47/14068?source=see_link\">",
"    see \"Doxylamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1657880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldex&reg; AN",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F1657881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Unisom&reg;-2",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1657884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1657914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insomnia: Oral: One tablet 30 minutes before bedtime; once daily or as instructed by healthcare professional",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F1657915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1657922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as succinate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aldex&reg; AN: 5 mg [orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2763813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1657886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of short-term insomnia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14446273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nausea and vomiting of pregnancy (NVP)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F1657877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Doxylamine may be confused with doxycycline",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F1657896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, disorientation, drowsiness, headache, paradoxical CNS stimulation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, dry mucous membranes, diarrhea, constipation, epigastric pain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1657891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxylamine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1657892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleeplessness: If sleeplessness persists for &gt;2 weeks, consult healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of this potent anticholinergic agent due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age; tolerance develops to hypnotic effects (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1657899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1657902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1657888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal use of doxylamine in combination with pyridoxine during pregnancy has not been shown to increase the baseline risk of major malformations. Doxylamine is recommended for the treatment of nausea and vomiting of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F1657889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1657890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doxylamine succinate is expected to be found in breast milk and adverse events (unusual excitement, irritability, sedation) may be expected in a nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Aldex AN Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $249.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Unisom Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (16): $5.45",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Calmex (CN);",
"     </li>",
"     <li>",
"      Donormyl (FR);",
"     </li>",
"     <li>",
"      Dozile (AU, NZ);",
"     </li>",
"     <li>",
"      Hoggar N (TH);",
"     </li>",
"     <li>",
"      Restavit (AU);",
"     </li>",
"     <li>",
"      Sedaplus (DE);",
"     </li>",
"     <li>",
"      Sleep Aid (IL);",
"     </li>",
"     <li>",
"      Sominar (TH);",
"     </li>",
"     <li>",
"      Somnil (ZA);",
"     </li>",
"     <li>",
"      Tonight (IL);",
"     </li>",
"     <li>",
"      Unisom (IL, PH, TR);",
"     </li>",
"     <li>",
"      Unsono (PT);",
"     </li>",
"     <li>",
"      Zarcop (CN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1657905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doxylamine competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells; blocks chemoreceptor trigger zone, diminishes vestibular stimulation, and depresses labyrinthine function through its central anticholinergic activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1657907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic by N-dealkylation to metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 10-12 hours (Paton, 1985; Friedman, 1985); may be increased in the elderly (Friedman, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-4 hours (Paton, 1985; Friedman, 1985; Friedman, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG (American College of Obstetricians and Gynecologists), \"Practice Bulletin: Nausea and Vomiting of Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 103(4):803-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17221/abstract-text/15051578/pubmed\" id=\"15051578\" target=\"_blank\">",
"        15051578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17221/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman H and Greenblatt DJ, The Pharmacokinetics of Doxylamine: Use of Automated Gas Chromatography With Nitrogen-Phosphorus Detection,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1985, 25(6):448-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17221/abstract-text/4056080/pubmed\" id=\"4056080\" target=\"_blank\">",
"        4056080",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman H, Greenblatt DJ, Scavone JM, et al, \"Clearance of the Antihistamine Doxylamine. Reduced In Elderly Men But Not In Elderly Women,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1989, 16(5):312-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17221/abstract-text/2743704/pubmed\" id=\"2743704\" target=\"_blank\">",
"        2743704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hausmann E, Kohl B, von Boehmer H, et al, &ldquo;False-Positive EMIT Indication of Opiates and Methadone in a Doxylamine Intoxication,&rdquo;",
"      <i>",
"       J Clin Chem Clin Biochem",
"      </i>",
"      , 1983, 21(10):599-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17221/abstract-text/6358402/pubmed\" id=\"6358402\" target=\"_blank\">",
"        6358402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paton DM and Webster DR, \"Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines),\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1985, 10(6):477-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17221/abstract-text/2866055/pubmed\" id=\"2866055\" target=\"_blank\">",
"        2866055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8796 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17221=[""].join("\n");
var outline_f16_52_17221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657880\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657881\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657884\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657914\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657915\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657922\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2763813\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657886\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14446273\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657877\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657896\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657891\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657892\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299235\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657899\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657902\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657888\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657889\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657890\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322880\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869455\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657905\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1657907\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8796|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/47/14068?source=related_link\">",
"      Doxylamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_52_17222="Slit lamp beam height";
var content_f16_52_17222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77853%7EEM%2F52336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77853%7EEM%2F52336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Slit lamp beam height",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adjust slit lamp beam for a tall, narrow vertical beam of white light.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Slit lamp beam width",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 490px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The slit width should be adjusted to make the beam as narrow as possible without causing the illumination to decrease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17222=[""].join("\n");
var outline_f16_52_17222=null;
var title_f16_52_17223="Poliovirus vaccination";
var content_f16_52_17223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Poliovirus vaccination",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/52/17223/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17223/contributors\">",
"     John F Modlin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/52/17223/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17223/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17223/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/52/17223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17223/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/52/17223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization against poliovirus infection represents one of the world's greatest medical achievements. The last cases of naturally occurring, wild type paralytic poliomyelitis in the United States occurred during a small outbreak due to type 1 poliovirus in an unvaccinated religious community in 1978-79 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/1\">",
"     1",
"    </a>",
"    ]. All nations in the western hemisphere, the Pacific region and Europe are now free of poliomyelitis.",
"   </p>",
"   <p>",
"    There are three countries with endemic polio: Pakistan, Afghanistan, and Nigeria. In January 2012, India marked the first year in history with no recorded new polio cases, a monumental achievement by a country that once harbored 85 percent of the global burden of paralytic polio. However, since 2003 there has been spread to an additional 18 countries previously free of polio [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/2\">",
"     2",
"    </a>",
"    ]. One of the largest epidemics emerged in the Republic of Congo in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paralytic poliomyelitis and the post-polio syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=see_link\">",
"     \"Polio and infectious diseases of the anterior horn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/45/5849?source=see_link\">",
"     \"Post-polio syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POLIOVIRUS VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both inactivated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    (IPV) and live, attenuated oral poliovirus vaccine (OPV) were developed in the 1950s and have been used worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The benefits and risks of each vaccine are discussed below.",
"   </p>",
"   <p>",
"    Trivalent IPV is the only vaccine available for routine infant and childhood immunization in the United States, and it is now the preferred vaccine for other developed countries because, unlike OPV, it does not cause vaccine associated paralytic poliomyelitis. However, because OPV maintains certain advantages for children in developing countries, including cost, ease of administration, and transmission of vaccine virus to unimmunized contacts, it is the vaccine currently recommended by the World Health Organization (WHO) Expanded Program on Immunization (EPI). The trivalent form of OPV has been the mainstay of EPI and the WHO Polio Eradication Program for many years, but type 1 and type 3 monovalent OPV vaccines and type 1 and 3 bivalent OPV vaccines have recently been introduced into some polio endemic areas because they are more immunogenic than trivalent OPV when given as a single dose [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INACTIVATED POLIOVIRUS VACCINE (IPV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPV is prepared by inactivation of naturally occurring polioviruses by treatment with dilute formalin. Four formulations of IPV vaccine are available in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IPOL: Contains IPV only",
"     </li>",
"     <li>",
"      Pediarix: Contains IPV, DTaP, and HepB vaccine; approved for use as a three dose primary series in infants born of hepatitis B surface antigen-negative women, beginning as early as six weeks of age",
"     </li>",
"     <li>",
"      Pentacel: Contains IPV, DTaP and Hib; approved for use in infants and children at 2, 4, 6, and 15 through 18 months of age",
"     </li>",
"     <li>",
"      Kinrix: Contains IPV and DTaP; approved for the fifth dose of DTaP and the fourth dose of IPV at four to six years in children whose previous DTaP doses were with Infanrix or Pediarix",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immune response and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutralizing antibodies are detectable to all three poliovirus types in &gt;93 percent of recipients after two doses, and 100 percent after the third dose [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Seroconversion and antibody titers are diminished with short intervals between doses (eg, one month) and also reduced in the presence of high titers of maternal antibody in young infants. However, when vaccine immunogenicity in young children was evaluated in a randomized controlled trial in Cuba in which IPV or placebo was administered at 6, 10, and 14 weeks of age, the seroconversion rates were 94, 83, and 100 percent for types 1, 2, and 3 poliovirus, respectively, indicating that three doses of vaccine may mitigate the potential interference of maternal antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detectable antibody persists at protective levels for at least five years, although geometric mean titers decline considerably [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/15\">",
"     15",
"    </a>",
"    ]. There is little reason for routine evaluation to check antibody titers among immunocompetent patients who have received three doses of IPV or OPV. These patients have &gt;97 percent likelihood of complete immunity to all three serotypes. In some cases, the level of antibody may fall below detectable levels over time, but these patients are probably protected by immunologic memory.",
"   </p>",
"   <p>",
"    Data are limited regarding vaccine efficacy of IPV in developing countries. A case control study of IPV in Senegal demonstrated protection rates for recipients of one and two doses (36 and 89 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/16\">",
"     16",
"    </a>",
"    ]. The likelihood of efficacy after three IPV doses is high since virtually all IPV recipients experience a substantial boost in antibody titer following a third dose [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/16\">",
"     16",
"    </a>",
"    ]. It has also been shown that vaccinating infants with a single fractional dose of IPV can induce priming and seroconversion in more than 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/17\">",
"     17",
"    </a>",
"    ]; further study in developing settings is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of local reactions following Vero cell derived IPV is the same as placebo, and there is no evidence that IPV is associated with serious reactions, including vaccine-associated paralytic poliomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LIVE ATTENUATED ORAL POLIOVIRUS VACCINE (OPV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Live attenuated oral poliovirus vaccines (OPV) were developed in primates by repeated passage of wild type polioviruses in cell culture and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OPV remains an important tool for control of wild-type poliovirus transmission in the developing world because of cost, ease of administration, induction of mucosal immunity, and transmission of OPV viruses from OPV-vaccinated children to their non-immune contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/18\">",
"     18",
"    </a>",
"    ]. As discussed below, trivalent OPV formulations have allowed for simplification of immunization schedules, although the monovalent and bivalent formulations have superior immunogenicity and may be more effective in the setting of an outbreak caused by a single poliovirus type.",
"   </p>",
"   <p>",
"    Unlike IPV, OPV causes very rare cases of vaccine-associated paralytic poliomyelitis (VAPP) in both recipients and their contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, the immune response to OPV is much less than optimal in settings with a high burden of infection with other enteric viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/20\">",
"     20",
"    </a>",
"    ]. In areas with inadequate vaccine coverage, OPV viruses can spread into the community and acquire neurovirulent traits similar to wild type polioviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other than vaccine-associated paralytic poliomyelitis, there are no adverse reactions attributed to OPV. The available data suggest that OPV does not increase the risk of fetal malformation or other adverse pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OPV vaccines are no longer licensed in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Trivalent vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trivalent formulations greatly simplify OPV administration. The formulations available globally contain approximately 10(6.5) 50 percent tissue culture infectious doses (TCID50), 10(5.5) TCID50, and 10(6.2) TCID50 of poliovirus types 1, 2, and 3, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/20\">",
"     20",
"    </a>",
"    ]. The unequal contribution of each type to the trivalent preparation represents a \"balanced\" formulation designed to account for the more efficient replication of type 2 OPV virus in the gastrointestinal tract; if type 2 were given in equal concentrations with types 1 and 3, it would interfere with the replication of the two latter types [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An optimal immune response to trivalent OPV requires multiple doses. In developed countries, three doses given at least two months apart are sufficient, with antibody prevalence to all three types being approximately 96 percent after the third dose [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/11\">",
"     11",
"    </a>",
"    ]. Detectable serum antibody to all three types persists in 84 to 98 percent of vaccinees five years after primary immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the efficacy of trivalent OPV has never been tested under conditions of exposure to natural polioviruses, more than three decades of OPV use in the United States from 1961 to 2000 provide overwhelming evidence of its effectiveness. OPV efficacy was directly evaluated during a type 1 poliovirus outbreak in Taiwan in the early 1980s. During this outbreak, vaccine efficacy was estimated to be 82, 96, and 98 percent for one, two, and three or more doses, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In tropical countries, the series of trivalent OPV at 6, 10, and 14 weeks of age recommended by the WHO Expanded Program for Immunization (EPI) fails to produce active immunity in a significant proportion of infants. Low seroconversion rates after this three dose regimen have been documented in many locations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/26-30\">",
"     26-30",
"    </a>",
"    ], averaging 73, 90, and 70 percent for types 1, 2, and 3, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/20\">",
"     20",
"    </a>",
"    ]. Diarrheal disease at the time of immunization is a major factor. One study conducted in Brazil and Gambia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/20,31\">",
"     20,31",
"    </a>",
"    ], and another one conducted in Bangladesh [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/32\">",
"     32",
"    </a>",
"    ] convincingly showed that diarrhea reduced seroconversion rates to types 2 and 3 OPV, while the response to type 1 was not affected. The impact of diarrhea on seroconversion persists despite the administration of three or four OPV doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Monovalent and bivalent vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monovalent (types 1 and 3) and bivalent (types 1 and 3) poliovirus vaccines have been developed to enhance global poliovirus eradication efforts in resource limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This is an attractive approach because monovalent and bivalent OPV vaccines are more immunogenic than trivalent OPV for the corresponding serotype, given the absence of interference from type 2 poliovirus in the trivalent formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/9,10,33\">",
"     9,10,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in Egypt, India, and South Africa have demonstrated that both monovalent type 1 and monovalent type 3 OPV and bivalent type 1 and 3 OPV are superior to trivalent OPV in inducing humoral antibodies against the relevant serotypes in newborn infants and following supplemental immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/10,34\">",
"     10,34",
"    </a>",
"    ]. This finding was not observed in Pakistan and Afghanistan, however, perhaps due to high prevalence of enteric infections and inadequate vaccine coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/35\">",
"     35",
"    </a>",
"    ]. Monovalent vaccination may also be more effective for protection in response to an outbreak caused by a single poliovirus type [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/9\">",
"     9",
"    </a>",
"    ]. Deployment of these OPV formulations in India and Africa is credited with much of the progress towards global poliomyelitis eradication",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infants who receive OPV have stool shedding of Sabin strain viruses with enhanced replicative ability due to a back mutation in the 5' non-coding region of the RNA genome; these are known as vaccine-derived polioviruses (VDPV). This phenomenon is observed with all vaccine serotypes and is associated with vaccine-associated paralytic poliomyelitis (VAPP).",
"   </p>",
"   <p>",
"    VAPP is a rare but important adverse event due to OPV administration; in the United States between 1961 and 1997 it was reported in an average of nine persons per year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. VAPP continues to be observed in regions where OPV is employed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VAPP usually occurs among young infant OPV recipients and among direct contacts of OPV recipients (mostly adult caretakers with inadequate vaccination). The overall risk is about 1 case per 900,000 first dose OPV recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/38\">",
"     38",
"    </a>",
"    ]. Subsequent doses are far less likely to be associated with VAPP. Adults may be at higher risk than young infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/19\">",
"     19",
"    </a>",
"    ]. Persons with B cell immunodeficiency carry the highest risk with an estimated VAPP rate of 2 per 1000 vaccinees [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. For this reason, OPV is contraindicated for immunodeficient individuals.",
"   </p>",
"   <p>",
"    Outbreaks of paralytic poliomyelitis due to virulent polioviruses derived from OPV vaccine strains have occurred among under immunized children living in resource limited settings. Low immunization rates in these areas permit virus circulation for prolonged periods of time, allowing acquisition of biological properties that are indistinguishable from naturally occurring wild polioviruses by continuous mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/21,43-45\">",
"     21,43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The emergence of VDPV has influenced plans for the eventual cessation of poliovirus immunization following eradication of poliomyelitis which will include a strategy to discontinue OPV use worldwide, introduction of IPV in as many countries as feasible, development of an OPV vaccine stockpile, and a plan for containment of laboratory stocks of naturally occurring and attenuated polioviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPV is the only vaccine recommended by the Centers for Disease Control and Prevention, the Advisory Committee on Immunization Practices (ACIP), and the American Academy of Pediatrics for routine immunization in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. OPV is no longer licensed or distributed in the United States. Vaccines containing IPV are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef78224 \" href=\"UTD.htm?2/8/2189\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polio vaccination series in the United States consists of four doses of IPV administered subcutaneously or intramuscularly [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/51\">",
"     51",
"    </a>",
"    ]. The first and second doses are administered at two and four months of age, respectively. The third dose is usually given at 6 to 18 months of age; and a fourth dose is routinely given at four to six years before school entry [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/52\">",
"     52",
"    </a>",
"    ]. The minimum interval between doses one and two and between doses two and three is four weeks, and the minimum interval between doses three and four is six months. The minimum age for dose one is six weeks. Minimal age and intervals should be used when there is imminent threat of exposure, such as travel to an area in which polio is endemic or epidemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who are inadequately vaccinated should complete the vaccination series. The fourth dose is not required if the third dose of IPV was delayed until after the child's fourth birthday.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine poliovirus vaccination is not necessary in adults residing in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/49\">",
"     49",
"    </a>",
"    ]. Such individuals are at minimal risk for exposure and most are adequately protected because of vaccination during childhood. However, vaccination is recommended for individuals are increased risk for exposure. This includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Travelers to areas or countries when polio is endemic or epidemic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link&amp;anchor=H7672819#H7672819\">",
"       \"Immunizations for travel\", section on 'Poliovirus vaccine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Members of communities or population groups with disease caused by wild polioviruses.",
"     </li>",
"     <li>",
"      Unvaccinated adults whose children will receive OPV.",
"     </li>",
"     <li>",
"      Healthcare workers who have close contract with patients who might be excreting wild polioviruses or laboratory workers who handle specimens that may contain polioviruses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adults at increased risk who have had a primary vaccination series with IPV or OPV should receive a single booster dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose of IPV.",
"   </p>",
"   <p>",
"    Adults who are unvaccinated or whose vaccination status is not documented should receive a primary vaccination series with IPV. This consists of two doses of IPV at four to eight week intervals and a third dose 6 to 12 months after the second dose. If this regimen cannot be completed within the recommended intervals before protection is needed, the following alternatives are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there are more than eight weeks before protection is needed, three doses of IPV should be given at least four weeks apart.",
"     </li>",
"     <li>",
"      If there are only four to eight weeks before protection is needed, two doses of IPV should be given at least four weeks apart.",
"     </li>",
"     <li>",
"      If there are less than four weeks before protection is needed, a single dose of IPV should be given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the second and third options, the remaining doses should be given later at the recommended intervals if the person remains at risk for exposure to poliovirus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although adverse effects of IPV have not been documented in either the mother or fetus, vaccination is not recommended during pregnancy on theoretical grounds [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. If, however, a pregnant woman is at increased risk for infection and requires immediate protection, IPV should be given according to the above schedule in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H25#H25\">",
"     \"Immunizations during pregnancy\", section on 'Poliovirus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPV is the only vaccine recommended for immunodeficient individuals and their household contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/53\">",
"     53",
"    </a>",
"    ]. However, a protective immune response cannot be assured in patients who are immunodeficient at the time of vaccination. The response in hematopoietic cell transplant recipients is optimized when more than one dose is administered at least 12 months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17223/abstract/21,54,55\">",
"     21,54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H5#H5\">",
"     \"Immunizations in HIV-infected patients\", section on 'Poliovirus vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/57/8082?source=see_link\">",
"       \"Patient information: Poliomyelitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/1\">",
"      Kim-Farley RJ, Bart KJ, Schonberger LB, et al. Poliomyelitis in the USA: virtual elimination of disease caused by wild virus. Lancet 1984; 2:1315.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Polio Eradication. Wild Poliovirus Weekly Update, 2009. file://www.polioeradication.org/casecount.asp (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/3\">",
"      Patel MK, Konde MK, Didi-Ngossaki BH, et al. An outbreak of wild poliovirus in the Republic of Congo, 2010-2011. Clin Infect Dis 2012; 55:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/4\">",
"      Gregory CJ, Ndiaye S, Patel M, et al. Investigation of elevated case-fatality rate in poliomyelitis outbreak in Pointe Noire, Republic of Congo, 2010. Clin Infect Dis 2012; 55:1299.",
"     </a>",
"    </li>",
"    <li>",
"     Francis, T, Napier, JA, Voight, RB, et al. Evaluation of the 1954 Field Trial of Poliomyelitis Vaccine. Final Report. Vaccine Evaluation Center, Department of Epidemiology, University of Michigan, Ann Arbor, MI 1957.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/6\">",
"      Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985; 151:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/7\">",
"      SALK JE. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc 1953; 151:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/8\">",
"      Grassly NC, Fraser C, Wenger J, et al. New strategies for the elimination of polio from India. Science 2006; 314:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/9\">",
"      C&aacute;ceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001; 33:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/10\">",
"      Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010; 376:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/11\">",
"      McBean AM, Thoms ML, Albrecht P, et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988; 128:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/12\">",
"      Simoes EA, John TJ. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J Biol Stand 1986; 14:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/13\">",
"      Asturias EJ, Dueger EL, Omer SB, et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis 2007; 196:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/14\">",
"      Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007; 356:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/15\">",
"      Swartz TA, Handsher R, Stoeckel P, et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 1989; 5:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/16\">",
"      Robertson SE, Traverso HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988; 1:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/17\">",
"      Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/18\">",
"      SABIN AB. Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc 1957; 164:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/19\">",
"      HENDERSON DA, WITTE JJ, MORRIS L, LANGMUIR AD. PARALYTIC DISEASE ASSOCIATED WITH ORAL POLIO VACCINES. JAMA 1964; 190:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/20\">",
"      Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/21\">",
"      Kew OM, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 2004; 82:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/22\">",
"      Harjulehto T, Aro T, Hovi T, Sax&eacute;n L. Congenital malformations and oral poliovirus vaccination during pregnancy. Lancet 1989; 1:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/23\">",
"      ROBERTSON HE, ACKER MS, DILLENBERG HO, et al. Community-wide use of a \"balanced\" trivalent oral poliovirus vaccine (Sabin). A report of the 1961 trial at Prince Albert, Saskatchewan. Can J Public Health 1962; 53:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/24\">",
"      Krugman RD, Hardy GE Jr, Sellers C, et al. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine. Pediatrics 1977; 60:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/25\">",
"      Kim-Farley RJ, Rutherford G, Lichfield P, et al. Outbreak of paralytic poliomyelitis, Taiwan. Lancet 1984; 2:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/26\">",
"      John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972; 96:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/27\">",
"      John TJ. Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection. Am J Epidemiol 1975; 102:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/28\">",
"      D&ouml;m&ouml;k I, Balayan MS, Fayinka OA, et al. Factors affecting the efficacy of live poliovirus vaccine in warm climates. Efficacy of type 1 Sabin vaccine administered together with antihuman gamma-globulin horse serum to breast-fed and artificially fed infants in Uganda. Bull World Health Organ 1974; 51:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/29\">",
"      de Brito Bastos NC, Carvalho Filho ES de+CARVALHOAAFILHO ES, Schatzmayr H, et al. Antipoliomyelitis program in Brazil; a erologic study of immunity levels. Bull Pan Am Health Organ 1974; 8:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/30\">",
"      Lasch EE, Abed Y, Abdulla K, et al. Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 1984; 6 Suppl 2:S467.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Collaborative Study Group on Oral Poliovirus Vaccine. Effect of diarrhea on seroconversion to oral poliovirus vaccine. In: 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim CA 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/32\">",
"      Myaux JA, Unicomb L, Besser RE, et al. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J 1996; 15:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/33\">",
"      Grassly NC, Jafari H, Bahl S, et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis 2009; 200:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/34\">",
"      el-Sayed N, el-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 2008; 359:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/35\">",
"      O'Reilly KM, Durry E, ul Islam O, et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis. Lancet 2012; 380:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/36\">",
"      Minor PD, Dunn G, Ramsay ME, Brown D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J Med Virol 2005; 75:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/37\">",
"      DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med 2011; 364:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/38\">",
"      Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004; 292:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/39\">",
"      Nkowane BM, Wassilak SG, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 1987; 257:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/40\">",
"      Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992; 14:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/41\">",
"      Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 1994; 11:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/42\">",
"      Wyatt HV. Letter: Risk of live poliovirus in immunodeficient children. J Pediatr 1975; 87:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/43\">",
"      Centers for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses--worldwide, January 2006-August 2007. MMWR Morb Mortal Wkly Rep 2007; 56:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/44\">",
"      Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/45\">",
"      Est&iacute;variz CF, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island--Indonesia, 2005. J Infect Dis 2008; 197:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/46\">",
"      Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/47\">",
"      Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. \"Endgame\" issues for the global polio eradication initiative. Clin Infect Dis 2002; 34:72.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Global Poliomyelitis Eradication Program. Global Eradication Initiative Strategic Plan, 2004-2008 file://www.polioeradication.org/content/publications/2004stratplan.pdf (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/49\">",
"      Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Infectious Diseases. Report of the Committee on Infectious Diseases 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/51\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep 2009; 58:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/52\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Poliovirus. Pediatrics 2011; 128:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/53\">",
"      Ehrenfeld E, Chumakov K. Monovalent oral poliovirus vaccines--a good tool but not a total solution. N Engl J Med 2008; 359:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/54\">",
"      Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17223/abstract/55\">",
"      Pauksen K, Hammarstr&ouml;m V, Ljungman P, et al. Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994; 18:547.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2695 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17223=[""].join("\n");
var outline_f16_52_17223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POLIOVIRUS VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INACTIVATED POLIOVIRUS VACCINE (IPV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immune response and efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LIVE ATTENUATED ORAL POLIOVIRUS VACCINE (OPV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Trivalent vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Monovalent and bivalent vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2695\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2695|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/8/2189\" title=\"table 1\">",
"      IPV formulations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/57/8082?source=related_link\">",
"      Patient information: Poliomyelitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=related_link\">",
"      Polio and infectious diseases of the anterior horn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/45/5849?source=related_link\">",
"      Post-polio syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_52_17224="Epithelial ovarian cancer: Pathology";
var content_f16_52_17224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epithelial ovarian cancer: Pathology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/52/17224/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17224/contributors\">",
"     Lee-may Chen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17224/contributors\">",
"     Jonathan S Berek, MD, MMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/52/17224/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17224/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/52/17224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17224/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/52/17224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis, incidence, epidemiology, and risk factors for epithelial ovarian cancer (EOC) will be reviewed here. Other issues, such as clinical manifestations, diagnosis, staging, treatment, and screening for ovarian cancer, and the nonepithelial primary ovarian tumors, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of primary ovarian tumors derive from epithelial cells on the surface of the ovary, although they can also arise from other cell types (germ cell tumors, sex cord-stromal tumors, and mixed cell type tumors).",
"   </p>",
"   <p>",
"    Epithelial cancer of the ovary derives from malignant transformation of the epithelium of the ovarian surface, which is contiguous with the peritoneal mesothelium (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/1\">",
"     1",
"    </a>",
"    ]. The molecular events leading to the development of EOC are unknown. Mutations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    overexpression of the oncogenes HER2 c-myc and K-ras, Akt, and of the tumor suppressor gene p53 have been observed in sporadic ovarian cancer, but their contribution to pathogenesis is not well defined [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Inactivation of the tumor suppressor genes PTEN and p16 may also occur. Epigenetic phenomenon also play a role in tumorigenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the molecular pathways underlying ovarian cancer progression are poorly understood. Although germline mutations in BRCA1, BRCA2, and other genes have been implicated in a small fraction of cases, epidemiologic and experimental evidence suggest that ovarian carcinogenesis is predominantly driven by factors associated with reproduction and ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In addition, mucinous and nonmucinous ovarian tumors may have different causal mechanisms related to ovulatory life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two general hypotheses have been proposed to explain the pathogenesis of EOC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incessant ovulation with repeated trauma and repair to the ovarian epithelium, which afford an opportunity for genetic mutation and cellular neoplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. This theory is supported by the protective effect of multiparity and oral contraceptives on the incidence of EOC.",
"     </li>",
"     <li>",
"      Excess gonadotropin secretion, promoting high estrogen concentrations, which lead to epithelial proliferation, and, possibly, malignant transformation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/11\">",
"       11",
"      </a>",
"      ]. Other hormones also may contribute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other theories include high androgen concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/7,12\">",
"     7,12",
"    </a>",
"    ], inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and stromal hyperactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/15\">",
"     15",
"    </a>",
"    ] as risk factors and the protective role of",
"    <span class=\"nowrap\">",
"     progesterone/progestins",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tubal intraepithelial carcinoma (TIC) has been detected in the fimbria of BRCA carriers; its role in subsequent progression to invasive cancer of the ovary, peritoneum, or fallopian tube has been suggested but not proven [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Precursor lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact cell of origin of EOC is not known, nor has a premalignant precursor lesion of the ovary been defined, although several investigators have proposed histologic features of possible significance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In particular, complex ovarian cysts and other clinically suspicious abnormalities identified on ultrasound in postmenopausal women do not appear to be precursors of ovarian cancer; if benign, these lesions are",
"    <strong>",
"     NOT",
"    </strong>",
"    at risk for progression to malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is increasing evidence that the pathogenesis of low-grade serous carcinomas and of serous tumors of low malignant potential (ie, noninvasive borderline tumors, see below) involves similar genes and pathways, and is distinct from that of high-grade serous carcinomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The designation EOC is derived from the origin of these tumors, which arise from neoplastic transformation of coelomic epithelium and adjacent ovarian stroma. The histopathological categories of epithelial ovarian carcinomas according to the World Health Organization and the International Society of Gynecological Pathologists are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef71536 \" href=\"UTD.htm?32/16/33036\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/21\">",
"     21",
"    </a>",
"    ]. The different histologic types may be associated with different risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Types of nonepithelial ovarian cancers include sex-cord stromal tumors, which are derived from nongerm cell components of the gonads (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    ); germ cell tumors, which are derived from germ cells (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    ); and small cell tumors (origin unclear), which can be associated with hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/23\">",
"     23",
"    </a>",
"    ]. These origins are illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ovary can also be involved by metastatic disease, especially from breast cancer or Krukenberg tumors (mucin producing neoplastic signet-ring cells involving the ovarian stroma) from the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Epithelial carcinomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serous histology accounts for as many as 75 percent of ovarian cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/24\">",
"     24",
"    </a>",
"    ]. Mucinous and endometrioid tumors are less common (about 10 percent each), followed by clear cell tumors, Brenner (transitional cell) tumors, and undifferentiated carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. Some features of each of these types of carcinoma are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The histological pattern of serous tumors simulates the lining of the fallopian tube. Poorly differentiated forms of serous carcinomas (high-grade tumors, which account for the majority of cases) are grossly indistinguishable from other epithelial tumors. This histologic variant is often associated with concentric rings of calcification known as psammoma bodies.",
"      <br/>",
"      <br/>",
"      Although no universal grading schema exists for ovarian serous carcinoma, a two-tiered system (low-grade versus high-grade) has received increasing acceptance [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Histopathologic grade is of prognostic significance [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/30\">",
"       30",
"      </a>",
"      ], and may also be of predictive value in that low-grade tumors appear less chemotherapy responsive than are high-grade tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There is increasing evidence that the pathogenesis of low-grade serous carcinomas and of serous tumors of low malignant potential (ie, noninvasive borderline tumors, see below) involves similar genes and pathways, and is distinct from that of high-grade serous carcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. Clinical observations have been consistent with molecular and genomic investigations. Both tumors are characterized by a young age at diagnosis and a prolonged natural history [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/34\">",
"       34",
"      </a>",
"      ], and the clinical behavior of borderline tumors that recur as low-grade invasive serous carcinomas appears similar to that of newly diagnosed low-grade serous carcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/32\">",
"       32",
"      </a>",
"      ]. Other studies have shown that serous tumors of low malignant potential often coexist with low-grade serous carcinomas, and when they recur, frequently do so as low-grade serous carcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These findings have led some to hypothesize that low-grade serous ovarian carcinomas represent the natural progression of an undetected serous ovarian tumor of low malignant potential. However, there is no definitive evidence that low-grade serous carcinomas always arise from serous tumors of low malignant potential, and whether the two entities represent a continuum of tumor progression remains unproven. At present, low-grade and high-grade invasive serous ovarian tumors are treated similarly, at least initially.",
"     </li>",
"     <li>",
"      Mucinous borderline and benign tumors may resemble intestinal or endocervical epithelium. Among borderline tumors, intestinal type predominates (85 percent), while the two histologic types occur with equal frequency among benign tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. Mucinous carcinomas tend to remain confined to the ovaries longer than serous carcinomas and are the largest epithelial ovarian neoplasms, with a median diameter of 18 to 20 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/26,42\">",
"       26,42",
"      </a>",
"      ]. CA 125 levels may not be markedly elevated, but they tend to follow the course of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/43\">",
"       43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A clinical picture of pseudomyxoma peritonei may be present [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/26\">",
"       26",
"      </a>",
"      ]. In fact, primary ovarian mucinous tumors can be difficult to distinguish from metastatic mucinous tumors from the",
"      <span class=\"nowrap\">",
"       colon/rectum,",
"      </span>",
"      appendix, cervix, or pancreas. In general, primary tumors are usually large (&ge;10 cm) and unilateral whereas metastatic tumors tend to be small (&lt;10 cm) and bilateral [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link\">",
"       \"Cancer of the appendix and pseudomyxoma peritonei\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      At least some data suggest a poorer outcome from platinum-based first-line chemotherapy for mucinous as compared to nonmucinous epithelial ovarian cancers, although initial treatment is typically similar [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/43,46-48\">",
"       43,46-48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endometrioid tumors closely resemble the components of endometrial cancer. They occasionally arise from foci of endometriosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. Endometrioid histology appears to be associated with better survival than when compared to serous adenocarcinoma, regardless of disease stage or response to platinum-based therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clear cell carcinomas of the ovary have also been called mesonephroid carcinomas because their histologic features include \"clear cells\", similar to those seen in renal cell carcinomas. These tumors can also arise from endometriosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/28\">",
"       28",
"      </a>",
"      ]. Rarely, they may be associated with humorally mediated hypercalcemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"       \"Hypercalcemia of malignancy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with ovarian clear cell cancer frequently have a clinical history of endometriosis; most have stage I disease and there may be a large pelvic mass [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. Recurrences are more frequent than with other histologies, and the response rate to platinum- and taxane-based regimens is lower [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/43,53-55\">",
"       43,53-55",
"      </a>",
"      ]. Nevertheless, clear cell cancers are still treated similarly to other EOCs.",
"      <br/>",
"      <br/>",
"      Some data suggest that women with clear cell ovarian cancer have an increased risk of venous thromboembolism compared with other ovarian cancer histologies [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/56-58\">",
"       56-58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brenner tumors can be benign or malignant. Benign Brenner tumors are small, solid masses composed of nests of transitional epithelium within the fibrous stroma. Intermediate Brenner tumors are comprised of proliferating cells of low malignant potential. These are generally unilateral and multicystic, with a good prognosis. Malignant Brenner tumors are comprised of frankly malignant cells with atypical features and invasive characteristics.",
"     </li>",
"     <li>",
"      Undifferentiated carcinoma refers to tumors with no discernible histologic differentiation or only minor areas of differentiation.",
"     </li>",
"     <li>",
"      Mixed carcinomas are those containing two or more distinct histologic types of cancer with each subtype involving at least 10 percent of the tumor mass. The presence of serous carcinoma or sarcoma as one of the components worsens the prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Borderline tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of low malignant potential are also called borderline tumors; they represent approximately 10 percent of malignant ovarian neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/12\">",
"     12",
"    </a>",
"    ]. This heterogeneous group of lesions is defined histologically by atypical epithelial proliferation without stromal invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=see_link\">",
"     \"Ovarian tumors of low malignant potential\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship of borderline tumors to invasive serous epithelial ovarian cancers remains uncertain. As noted above, there is increasing molecular, genomic, and clinical evidence that low-grade invasive serous epithelial carcinomas and serous tumors of low malignant potential have a common pathogenesis, shared genes and pathways, and clinical behavior, distinct from those of high-grade serous carcinomas. However, there is no definitive evidence that low-grade serous carcinomas always arise from serous tumors of low malignant potential, and whether the two entities represent a continuum of tumor progression remains unproven. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Epithelial carcinomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peritoneal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal carcinoma (also known as serous carcinoma of the peritoneum) is another entity closely associated with, but distinct from, EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/61-66\">",
"     61-66",
"    </a>",
"    ]. Histologically, this tumor is indistinguishable from serous ovarian carcinoma, but morphologic distinctions have been described. The criteria established by the Gynecologic Oncology Group (GOG) to define peritoneal carcinoma are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ovaries normal in size (4.0 cm in largest diameter) or enlarged by a benign process",
"     </li>",
"     <li>",
"      Extraovarian involvement greater than ovarian involvement",
"     </li>",
"     <li>",
"      A predominantly serous histology",
"     </li>",
"     <li>",
"      Surface involvement of less than 5 mm depth and width",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using these criteria, between 7 and 20 percent of patients previously identified with primary EOC may be reclassified as having peritoneal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/63-65,67\">",
"     63-65,67",
"    </a>",
"    ]. Some data suggest that peritoneal carcinoma may originate in the fallopian tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/68\">",
"     68",
"    </a>",
"    ]. In some cases, they may be classified as adenocarcinomas of unknown primary site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link&amp;anchor=H10#H10\">",
"     \"Adenocarcinoma of unknown primary site\", section on 'Women with peritoneal carcinomatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pattern of spread is similar to that in women with EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Women with serous carcinoma of the peritoneum are treated similarly to those with EOC. Optimal surgical cytoreduction may be more difficult to achieve in the setting of widespread peritoneal disease without a predominant ovarian or pelvic mass. Chemotherapy regimens and response rates are similar to EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritoneal carcinoma is surgically staged according the",
"    <span class=\"nowrap\">",
"     FIGO/TNM",
"    </span>",
"    staging system (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant mixed mesodermal sarcomas of the ovary (also called ovarian carcinosarcomas) are rare and aggressive tumors with a poor prognosis. Most occur in postmenopausal women with presentation similar to that with EOCs. Optimal treatment has not been established by prospective trials, but in most patients, consists of cytoreductive surgery and postoperative chemotherapy using platinum-containing combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/59,72-78\">",
"     59,72-78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATTERNS OF SPREAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial ovarian cancers can spread intraperitoneally, via lymphatic channels, or by hematogenous dissemination. The most common and earliest mode of spread is by exfoliation of cells that implant along the surfaces of the peritoneal cavity. The cells tend to follow the circulatory path of peritoneal fluid, often moving with the forces of respiration from the pelvis, up the paracolic gutters (especially on the right), along the intestinal mesentery, to the right hemidiaphragm. These implanted cells give rise to metastatic foci in the posterior cul-de-sac, the paracolic gutters, on the diaphragmatic surface, the liver capsule, the surface of the intestines, and the omentum. The disease seldom invades the intestinal lumen, but progressively agglutinates loops of bowel leading to functional intestinal obstruction, or carcinomatous ileus.",
"   </p>",
"   <p>",
"    Lymphatic dissemination to the pelvic and paraaortic lymph nodes is common, particularly in clinically advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Spread through the lymphatic channels of the retroperitoneal lymph nodes and the diaphragm can lead to dissemination of disease into the supraclavicular lymph nodes and pleural space.",
"   </p>",
"   <p>",
"    Hematogenous dissemination at the time of diagnosis is uncommon, with only 2 to 3 percent of patients found to have parenchymal involvement of the lungs or liver. Brain metastases are rare.",
"   </p>",
"   <p>",
"    Pleural effusion is the most common finding constituting stage IV disease, followed by parenchymal liver metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/81\">",
"     81",
"    </a>",
"    ]. Most patients with disease above the diaphragm have a right pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sporadic EOC commonly remains confined to the peritoneum even when advanced. In contrast, BRCA-associated cases frequently metastasize to viscera. In a report that compared disease distribution among 19 patients with EOC or a peritoneal carcinoma in the setting of a germline BRCA1 or 2 mutation versus 38 matched nonhereditary controls, visceral metastases were present in 74 versus 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17224/abstract/83\">",
"     83",
"    </a>",
"    ]. The most common sites of involvement were liver, lung, and spleen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"       \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of primary ovarian tumors derive from epithelial cells on the surface of the ovary, although they can also arise from other cell types (germ cell tumors, sex cord-stromal tumors, and mixed cell type tumors) (",
"      <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The molecular pathways underlying ovarian cancer progression are poorly understood. Although germline mutations in BRCA1, BRCA2, and other genes have been implicated in a small fraction of cases, epidemiologic and experimental evidence suggests that ovarian carcinogenesis is predominantly driven by factors associated with reproduction and ovulation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The exact cell of origin of EOC is not known, nor has a premalignant precursor lesion of the ovary been defined, although several investigators have proposed histologic features of possible significance. In particular, complex ovarian cysts and other clinically suspicious abnormalities identified on ultrasound in postmenopausal women do not appear to be precursors of ovarian cancer; if benign, these lesions are",
"      <strong>",
"       NOT",
"      </strong>",
"      at risk for progression to malignancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Precursor lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serous histology accounts for as many as 75 percent of ovarian cancers. Mucinous and endometrioid tumors are less common (about 10 percent each), followed by clear cell tumors, Brenner (transitional cell) tumors, and undifferentiated carcinomas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epithelial carcinomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumors of low malignant potential are also called borderline tumors; they represent approximately 10 percent of malignant ovarian neoplasms. This heterogeneous group of lesions is defined histologically by atypical epithelial proliferation without stromal invasion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Borderline tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peritoneal carcinoma (also known as serous carcinoma of the peritoneum) is another entity closely associated with, but distinct from, epithelial ovarian cancer. Histologically, this tumor is indistinguishable from serous ovarian carcinoma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Peritoneal carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/1\">",
"      Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/2\">",
"      Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000; 16:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/3\">",
"      Havrilesky L, Darcy kM, Hamdan H, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21:3814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/4\">",
"      Verri E, Guglielmini P, Puntoni M, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005; 68:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/5\">",
"      Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/6\">",
"      Banks E, Beral V, Reeve G. The epidemiology of epithelial ovarian cancer: a review. Int J Gynecol Cancer 1997; 7:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/7\">",
"      Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/8\">",
"      Purdie DM, Siskind V, Bain CJ, et al. Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 2001; 153:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/9\">",
"      Casagrande JT, Louie EW, Pike MC, et al. \"Incessant ovulation\" and ovarian cancer. Lancet 1979; 2:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/10\">",
"      Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia? Lancet 1971; 2:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/11\">",
"      Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/12\">",
"      Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995; 274:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/13\">",
"      Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000; 11:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/14\">",
"      McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007; 109:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/15\">",
"      Cramer DW, Barbieri RL, Fraer AR, Harlow BL. Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age. Hum Reprod 2002; 17:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/16\">",
"      Modugno F, Ovarian Cancer and High-Risk Women Symposium Presenters. Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 2003; 91:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/17\">",
"      Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/18\">",
"      Casey MJ, Bewtra C, Hoehne LL, et al. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol Oncol 2000; 78:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/19\">",
"      Barakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000; 89:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/20\">",
"      Hartge P, Hayes R, Reding D, et al. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial. Am J Obstet Gynecol 2000; 183:1232.",
"     </a>",
"    </li>",
"    <li>",
"     Serov SF, Scully RE, Sobin IH. histological classification of tumors no. 9. histological typing of ovarian tumours, World Health Organization, Geneva 1973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/22\">",
"      Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 2005; 96:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/23\">",
"      Harrison ML, Hoskins P, du Bois A, et al. Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study. Gynecol Oncol 2006; 100:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/24\">",
"      Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol 1996; 60:393.",
"     </a>",
"    </li>",
"    <li>",
"     Scully RE, Young RH, Clement PB. Surface epithelial-stromal tumors and serous tumors. In: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament, Armed Forces Institute of Pathology, Washington, DC 1998.",
"    </li>",
"    <li>",
"     Scully RE, Young RH, Clement PB. Mucinous tumors and pseudomyxoma peritonei. In: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament, Armed Forces Institute of Pathology, Washington, DC 1998.",
"    </li>",
"    <li>",
"     Scully RE, Young RH, Clement PB. Endometrioid tumors. In: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament, Armed Forces Institute of Pathology, Washington, DC 1998. p.107.",
"    </li>",
"    <li>",
"     Scully RE, Young RH, Clement PB. Clear cell tumors. In: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament, Armed Forces Institute of Pathology, Washington, DC 1998.",
"    </li>",
"    <li>",
"     Scully RE, Young RH, Clement PB. Transitional and squamous cell tumors. In: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament, Armed Forces Institute of Pathology, Washington, DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/30\">",
"      Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000; 19:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/31\">",
"      Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/32\">",
"      Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009; 114:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/33\">",
"      Schmeler KM, Sun CC, Bodurka DC, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008; 108:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/34\">",
"      Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006; 108:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/35\">",
"      Singer G, St&ouml;hr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/36\">",
"      Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65:10602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/37\">",
"      Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/38\">",
"      Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002; 99:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/39\">",
"      Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (&gt; or =5-year) follow-up. Am J Surg Pathol 2005; 29:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/40\">",
"      Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 2000; 24:1447.",
"     </a>",
"    </li>",
"    <li>",
"     Prat, J. Ovarian serous and mucinous epithelial-stromal tumors. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed., Robboy, SJ, Mutter, GL, Prat, J, Bentley, RC, Russell, P, Anderson, MC (Eds), Churchill Livingstone Elsevier, Philadelphia 2009. p.635-639.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/42\">",
"      Seidman JD, Ronnett BM, Kurman RJ. Pathology of borderline (low malignant potential) ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2002; 16:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/43\">",
"      Tian C, Markman M, Zaino R, et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer 2009; 115:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/44\">",
"      Khunamornpong S, Suprasert P, Pojchamarnwiputh S, et al. Primary and metastatic mucinous adenocarcinomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol 2006; 101:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/45\">",
"      Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/46\">",
"      Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/47\">",
"      Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 2010; 116:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/48\">",
"      Alexandre J, Ray-Coquard I, Selle F, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol 2010; 21:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/49\">",
"      Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol 1990; 75:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/50\">",
"      McMeekin DS, Burger RA, Manetta A, et al. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol 1995; 59:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/51\">",
"      Storey DJ, Rush R, Stewart M, et al. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. Cancer 2008; 112:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/52\">",
"      Pectasides D, Pectasides E, Psyrri A, Economopoulos T. Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 2006; 11:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/53\">",
"      Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/54\">",
"      Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/55\">",
"      Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88:2584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/56\">",
"      Duska LR, Garrett L, Henretta M, et al. When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol 2010; 116:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/57\">",
"      Rodriguez AO, Wun T, Chew H, et al. Venous thromboembolism in ovarian cancer. Gynecol Oncol 2007; 105:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/58\">",
"      Eltabbakh GH, Mount SL, Beatty B, et al. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J Surg Oncol 2006; 93:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/59\">",
"      Brown E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004; 100:2148.",
"     </a>",
"    </li>",
"    <li>",
"     Russell P. Surface epithelial-stromal tumors of the ovary. In: Blaustein's pathology of the female genital tract, 4th, Kurman RJ (Ed), Verlag, New York 1994. p.705.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/61\">",
"      SWERDLOW M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol 1959; 77:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/62\">",
"      Gooneratne S, Sassone M, Blaustein A, Talerman A. Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases. Int J Gynecol Pathol 1982; 1:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/63\">",
"      Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989; 64:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/64\">",
"      Lele SB, Piver MS, Matharu J, Tsukada Y. Peritoneal papillary carcinoma. Gynecol Oncol 1988; 31:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/65\">",
"      Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990; 75:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/66\">",
"      Barda G, Menczer J, Chetrit A, et al. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 2004; 190:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/67\">",
"      Mills SE, Andersen WA, Fechner RE, Austin MB. Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. Am J Surg Pathol 1988; 12:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/68\">",
"      Seidman JD, Zhao P, Yemelyanova A. \"Primary peritoneal\" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011; 120:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/69\">",
"      Eltabbakh GH, Mount SL. Lymphatic spread among women with primary peritoneal carcinoma. J Surg Oncol 2002; 81:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/70\">",
"      Dubernard G, Morice P, Rey A, et al. Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma. Gynecol Oncol 2005; 97:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/71\">",
"      Bloss JD, Brady MF, Liao SY, et al. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol 2003; 89:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/72\">",
"      As AK, Webb JB, Chowdhury RR. Malignant mixed mesodermal tumour of the ovary: clinicopathological features. J Obstet Gynaecol 1999; 19:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/73\">",
"      Le T, Krepart GV, Lotocki RJ, Heywood MS. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience. Gynecol Oncol 1997; 65:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/74\">",
"      Chang J, Sharpe JC, A'Hern RP, et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol 1995; 6:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/75\">",
"      Bicher A, Levenback C, Silva EG, et al. Ovarian malignant mixed m&uuml;llerian tumors treated with platinum-based chemotherapy. Obstet Gynecol 1995; 85:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/76\">",
"      Duska LR, Garrett A, Eltabbakh GH, et al. Paclitaxel and platinum chemotherapy for malignant mixed m&uuml;llerian tumors of the ovary. Gynecol Oncol 2002; 85:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/77\">",
"      Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2007; 105:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/78\">",
"      Silasi DA, Illuzzi JL, Kelly MG, et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008; 18:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/79\">",
"      Burghardt E, Pickel H, Lahousen M, Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986; 155:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/80\">",
"      Chen SS, Lee L. Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary. Gynecol Oncol 1983; 16:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/81\">",
"      Dauplat J, Hacker NF, Nieberg RK, et al. Distant metastases in epithelial ovarian carcinoma. Cancer 1987; 60:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/82\">",
"      Julian CG, Goss J, Blanchard K, Woodruff JD. Biologic behavior of primary ovarian malignancy. Obstet Gynecol 1974; 44:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17224/abstract/83\">",
"      Gourley C, Michie CO, Roxburgh P, et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol 2010; 28:2505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3241 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17224=[""].join("\n");
var outline_f16_52_17224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Precursor lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Epithelial carcinomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Borderline tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATTERNS OF SPREAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3241|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44307\" title=\"figure 1\">",
"      Origins ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/16/33036\" title=\"table 1\">",
"      Pathology of ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 2\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=related_link\">",
"      Adenocarcinoma of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=related_link\">",
"      Ovarian tumors of low malignant potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_52_17225="Rifampin (rifampicin): Pediatric drug information";
var content_f16_52_17225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rifampin (rifampicin): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"    see \"Rifampin (rifampicin): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/42/37541?source=see_link\">",
"    see \"Rifampin (rifampicin): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rifadin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rifadin&reg;;",
"     </li>",
"     <li>",
"      Rofact&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitubercular Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V., Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       H. influenzae",
"      </i>",
"      prophylaxis:",
"     </b>",
"     10 mg/kg/day once daily for 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningococcal prophylaxis:",
"     </b>",
"     10 mg/kg/day in divided doses every 12 hours for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      , synergy for infections:",
"     </b>",
"     5-20 mg/kg/day in divided doses every 12 hours with other antibiotics",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"      see \"Rifampin (rifampicin): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tuberculosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Active infection, treatment:",
"     <b>",
"      Note:",
"     </b>",
"     A four-drug regimen (isoniazid, rifampin, pyrazinamide, and ethambutol) is preferred for the initial, empiric treatment of TB. The regimen should be altered based on drug susceptibility results as appropriate. In HIV-exposed/positive patients, rifabutin may be used an alternative to rifampin. American Thoracic Society and CDC currently recommend twice weekly therapy as part of a short-course regimen, which follows 1-2 months of daily treatment of uncomplicated pulmonary tuberculosis in the compliant patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Daily therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children: 10-20 mg/kg/day (maximum dose: 600 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults: 10 mg/kg/day administered once daily (maximum dose: 600 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Directly observed therapy (DOT):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children: 10-20 mg/kg (maximum dose: 600 mg) administered 2 times/week if HIV negative",
"     <b>",
"      or",
"     </b>",
"     administered 3 times weekly if HIV-exposed/positive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults: 10 mg/kg (maximum dose: 600 mg) administered 2 or 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Latent tuberculosis infection (LTBI) treatment (as an alternative to isoniazid):",
"     <b>",
"      Note:",
"     </b>",
"     Combination with pyrazinamide should not generally be offered (",
"     <i>",
"      MMWR",
"     </i>",
"     , Aug 8, 2003). In HIV-exposed/positive patients, isoniazid is preferred due to potential for drug interactions of rifampin with antiretroviral therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children: 10-20 mg/kg/day once daily for 4 months (maximum dose: 600 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults: 10 mg/kg/dose once daily for 4 months (maximum dose: 600 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Primary prophylaxis of isoniazid-resistant tuberculosis in HIV-exposed/positive patients: Infants and Children: 10-20 mg/kg/dose once daily for 4-6 months (maximum dose: 600 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endocarditis, prosthetic valve due to MRSA",
"     </b>",
"     (Baddour, 2005; Lui, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 15-20 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 300 mg every 8 hours for at least 6 weeks (combine with vancomycin for the entire duration of therapy and gentamicin for the first 2 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       H. influenzae",
"      </i>",
"      prophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 20 mg/kg/day once daily for 4 days, not to exceed 600 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 600 mg once daily for 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningococcal prophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 20 mg/kg/day in divided doses every 12 hours for 2 days, not to exceed 600 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 600 mg every 12 hours for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      , nasal carriers:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 15 mg/kg/day divided every 12 hours for 5-10 days;",
"     <b>",
"      Note: Must use in combination with at least one other systemic antistaphylococcal antibiotic.",
"     </b>",
"     Not recommended as first-line drug for decolonization; evidence is weak for use in patients with recurrent infections (Liu, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 600 mg/day for 5-10 days;",
"     <b>",
"      Note: Must use in combination with at least one other systemic antistaphylococcal antibiotic.",
"     </b>",
"     Not recommended as first-line drug for decolonization; evidence is weak for use in patients with recurrent infections (Liu, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      , synergy for infections:",
"     </b>",
"     Adults: 600 mg once daily or 300-450 mg every 12 hours with other antibiotics.",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in combination with another antistaphylococcal antibiotic to avoid rapid development of resistance (Liu, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rifadin&reg;: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rifadin&reg;: 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer 1 hour before or 2 hours after a meal on an empty stomach; may administer with food to decrease GI distress; may mix contents of capsule with applesauce or jelly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Do not administer I.M. or SubQ; administer I.V. preparation once daily by slow I.V. infusion over 30 minutes to 3 hours at a final concentration not to exceed 6 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F218245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Diltiazem.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted I.V. solution is stable for 24 hours at room temperature; upon further dilution, it is stable for 4 hours in D",
"     <sub>",
"      5",
"     </sub>",
"     W and up to 24 hours in NS at room temperature. However, 11% to 13% rifampin decomposition has been reported to occur in 24 hours for solutions diluted in NS. Administer rifampin I.V. solution within 4 hours after preparation to avoid potential for precipitation and decomposition beyond this period.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of active tuberculosis in combination with other agents [FDA approved in pediatric patients (age not specified) and adults]; elimination of meningococci from asymptomatic carriers [FDA approved in pediatric patients (age not specified) and adults]; has also been used for  prophylaxis in contacts of patients with",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type B infection; used in combination with other anti-infectives in the treatment of staphylococcal infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rifadin&reg; may be confused with Rifater&reg;, Ritalin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rifampin may be confused with ribavirin, rifabutin, Rifamate&reg;, rifapentine, rifaximin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F218244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, behavioral changes, concentration impaired, confusion, dizziness, drowsiness, fatigue, fever, headache, numbness, psychosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pemphigoid reaction, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal insufficiency, menstrual disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, cramps, diarrhea, epigastric distress, flatulence, heartburn, nausea, pseudomembranous colitis, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (rare), DIC, eosinophilia, hemoglobin decreased, hemolysis, hemolytic anemia, leukopenia, thrombocytopenia (especially with high-dose therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis (rare), jaundice, LFTs increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, osteomalacia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Exudative conjunctivitis, visual changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, BUN increased, hemoglobinuria, hematuria, interstitial nephritis, uric acid increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rifampin, rifamycins, or any component; concurrent use with amprenavir",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with liver impairment, patients receiving concurrent medications associated with liver injury (particularly with pyrazinamide), or in patients with a history of alcoholism; modification of dosage should be considered in patients with severe liver impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Two month rifampin-pyrazinamide regimen for the treatment of latent tuberculosis infection (LTBI) has been associated with severe and fatal liver injuries. The IDSA and CDC now recommend that this regimen should not generally be used in patients with LTBI.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein, SLCO1B1;",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (strong), CYP2A6 (strong), CYP2B6 (strong), CYP2C19 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Rifamycin Derivatives may decrease the serum concentration of Alfentanil.  Management: Monitor closely for decreased alfentanil effectiveness.  Increased alfentanil doses will likely be needed.  Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Rifamycin Derivatives may increase the metabolism of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Rifamycin Derivatives may increase the metabolism of Angiotensin II Receptor Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Candesartan; Eprosartan; Olmesartan; Telmisartan; Valsartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Rifampin may increase the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): Rifamycin Derivatives may increase the metabolism of Antiemetics (5HT3 Antagonists).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dolasetron; Granisetron; Palonosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Rifamycin Derivatives may increase the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Rifampin may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Rifamycin Derivatives may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Rifamycin Derivatives may increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Rifamycin Derivatives may increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Rifamycin Derivatives may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: Rifampin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Rifampin may decrease the serum concentration of Bosentan. Following the initial several weeks of concurrent rifampin, this effect is most likely. Rifampin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few weeks of concurrent therapy (and may be greatest immediately following initiation of the combination).  Management: Weekly monitoring of liver function tests during the first 4 weeks of concurrent therapy is recommended, with a return to normal recommended monitoring thereafter as appropriate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Rifamycin Derivatives may decrease the serum concentration of BusPIRone.  Management: The degree to which rifampin alters buspirone concentrations warrants the consideration of an alternative to buspirone that is not metabolized by CYP3A4.  If these agents are used together, buspirone dose adjustments may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Rifamycin Derivatives may increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.  Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Rifampin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Rifampin may decrease the serum concentration of Caspofungin.  Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Rifampin may increase the metabolism of Chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Rifamycin Derivatives may enhance the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Rifampin may decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Rifamycin Derivatives may increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Rifamycin Derivatives may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inducers (Strong) may increase the metabolism of CYP1A2 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Rifamycin Derivatives may increase the metabolism of Dapsone (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Rifampin may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Rifampin may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May decrease the metabolism of Rifamycin Derivatives. Rifamycin Derivatives may increase the metabolism of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Rifamycin Derivatives may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Rifampin may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: Rifampin may decrease the serum concentration of Efavirenz.  Management: Increase efavirenz adult dose to 800 mg daily in patients weighing over 50 kg (per U.S. manufacturer; CDC sets this at 60 kg, and Canadian manufacturer recommends the dose increase regardless of weight).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Rifampin may decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Rifampin may increase the metabolism of Erlotinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Esomeprazole: Rifampin may decrease the serum concentration of Esomeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Rifamycin Derivatives may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Rifamycin Derivatives may decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Rifampin may decrease the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Rifamycin Derivatives. This appears only affect rifabutin. Rifamycin Derivatives may increase the metabolism of Fluconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Rifampin may decrease the serum concentration of Fosamprenavir. Specifically, concentrations of amprenavir (active metabolite) may be decreased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Rifampin may decrease the serum concentration of Fosaprepitant. More specifically, rifampin may decrease concentrations of the active metabolite aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Rifamycin Derivatives may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Rifamycin Derivatives may increase the metabolism of Gefitinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Rifamycin Derivatives may decrease the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Rifamycin Derivatives may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Rifampin may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Rifampin may increase the metabolism of LamoTRIgine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Rifampin may increase serum concentrations of the active metabolite(s) of Leflunomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Rifampin may enhance the adverse/toxic effect of Lopinavir. Specifically, the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Lopinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Rifamycin Derivatives may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Rifampin may decrease the serum concentration of Mirabegron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Morphine (Systemic): Rifamycin Derivatives may decrease the serum concentration of Morphine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Rifamycin Derivatives may decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Rifampin may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Rifampin may decrease the serum concentration of Nevirapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: Rifampin may decrease the serum concentration of Omeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OxyCODONE: Rifampin may decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Rifamycin Derivatives may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Rifamycin Derivatives may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: Rifampin may diminish the antiplatelet effect of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Rifamycin Derivatives may decrease the serum concentration of Propafenone.  Management: Monitor propafenone serum concentrations closely with rifamycin initiation/dose adjustments/discontinuation. Propafenone serum concentrations/therapeutic effects  may decrease with rifamycins. Propafenone dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyrazinamide: May enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.  Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Rifampin may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Rifampin may decrease the serum concentration of Raltegravir.  Management: Increase raltegravir dose to 800 mg twice daily (adult dose) when used concomitantly with rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Rifamycin Derivatives may increase the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Rifampin may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Rifamycin Derivatives may increase the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Rifamycin Derivatives may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Rifampin may decrease the serum concentration of Ritonavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: Rifampin may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining rifampin with roflumilast.  The Canadian product monograph makes no such recommendation but notes that rifampin may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Rifampin may enhance the adverse/toxic effect of Saquinavir. Specifically, the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Saquinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Rifampin may increase the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Rifampin may increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Rifamycin Derivatives may increase the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: Rifamycin Derivatives may increase the metabolism of Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Rifampin may decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus.  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as rifampin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): Rifampin may decrease the serum concentration of Terbinafine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Rifampin may decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Rifampin may decrease the serum concentration of Tipranavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Rifampin may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Rifamycin Derivatives may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zaleplon: Rifamycin Derivatives may increase the metabolism of Zaleplon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Rifamycin Derivatives may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Rifamycin Derivatives may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1049744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may delay and reduce the amount of rifampin absorbed",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been reported in animal studies. Rifampin crosses the human placenta. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to high. Postnatal hemorrhages have been reported in the infant and mother with isoniazid administration during the last few weeks of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic monitoring of liver function (AST, ALT); bilirubin, CBC, platelet count",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial RNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase, blocking RNA transcription",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Highly lipophilic; crosses the blood-brain barrier and is widely distributed into body tissues and fluids such as the liver, lungs, gallbladder, bile, tears, and breast milk; distributes into CSF when meninges are inflamed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes enterohepatic recycling; metabolized in the liver to a deacetylated metabolite (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 3-4 hours, prolonged with hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Principally in feces (60% to 65%) and urine (&sim;30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Plasma rifampin concentrations are not significantly affected by hemodialysis or peritoneal dialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/42/37541?source=see_link\">",
"      see \"Rifampin (rifampicin): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor urine, tears, sweat, or other body fluids to a red-orange color; soft contact lenses may be permanently stained. Notify physician of any severe or persistent flu-like symptoms, nausea, vomiting, dark urine, or unusual bleeding or bruising",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F218164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     A rifampin 1% w/v suspension (10 mg/mL) may be made with capsules and one of four syrups (Syrup NF, simple syrup, Syrpalta&reg; syrup, or raspberry syrup). Empty the contents of four 300 mg capsules or eight 150 mg capsules onto a piece of weighing paper. If necessary, crush contents to produce a fine powder. Transfer powder to a 4-ounce amber glass or plastic prescription bottle. Rinse paper and spatula with 20 mL of chosen syrup and add the rinse to bottle; shake vigorously. Add 100 mL syrup to the bottle and shake vigorously. Label \"shake well\". Stable for 4 weeks at room temperature or refrigerated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 25 mg/mL oral suspension may be made with capsules and cherry syrup concentrate diluted 1:4 with simple syrup, NF. Empty the contents of ten 300 mg capsules into a mortar and reduce to a fine powder. Add 20 mL of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle  sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\". Stable for 28 days refrigerated (preferred) or at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(1):161-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17225/abstract-text/1728006 /pubmed\" id=\"1728006 \" target=\"_blank\">",
"        1728006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, \"Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):394-434.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17225/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17225/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America 2003,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR11):3-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, \"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17225/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, \"Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17225/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR, &ldquo;Modern Approach to the Diagnosis and Treatment of Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1988, 35(3):441-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17225/abstract-text/3287309/pubmed\" id=\"3287309\" target=\"_blank\">",
"        3287309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR, &ldquo;Multidrug Therapy for Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(11):785-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17225/abstract-text/2124671/pubmed\" id=\"2124671\" target=\"_blank\">",
"        2124671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tan TQ, Mason EO Jr, Ou CN, et al, &ldquo;Use of Intravenous Rifampin in Neonates With Persistent Staphylococcal Bacteremia,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1993, 37(11):2401-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/52/17225/abstract-text/8285624 /pubmed\" id=\"8285624 \" target=\"_blank\">",
"        8285624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12767 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17225=[""].join("\n");
var outline_f16_52_17225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218187\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218188\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049735\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445007\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049726\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218158\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218142\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049738\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218245\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049730\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049737\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218247\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218244\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049742\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049725\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049724\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218233\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218151\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049744\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218154\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218169\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049734\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049723\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049741\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049732\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218164\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12767\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12767|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=related_link\">",
"      Rifampin (rifampicin): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/42/37541?source=related_link\">",
"      Rifampin (rifampicin): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_52_17226="Atrial arrhythmias (including AV block) in congenital heart disease";
var content_f16_52_17226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atrial arrhythmias (including AV block) in congenital heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/52/17226/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17226/contributors\">",
"     Samuel Asirvatham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17226/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17226/contributors\">",
"     Christopher J McLeod, MB, ChB, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/52/17226/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17226/contributors\">",
"     Hugh Calkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17226/contributors\">",
"     Charles I Berul, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/52/17226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/52/17226/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/52/17226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H181202946\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the striking successes in caring for patients with congenital heart disease (CHD) over the last few decades is improved longevity. Almost one million adults with CHD are now living in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]; up to half having undergone at least one open heart surgical procedure resulting in one or more residual atrial scars [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/4\">",
"     4",
"    </a>",
"    ]. For the purposes of this topic, CHD does not include bicuspid valves, but does include small ventricular and atrial septal defects.",
"   </p>",
"   <p>",
"    As a consequence of the both the added longevity and the atrial fibrosis and scarring resulting from many of the surgical procedures, atrial arrhythmias have been increasingly recognized in this group. They are a major cause of hospital admission and morbidity in patients with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. These rhythm abnormalities, which are often benign in the general population, may be poorly tolerated, and are associated with an almost 50 percent increase in mortality compared with those patients without atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although all forms of atrial bradycardia and tachycardia can adversely affect both children and adults with CHD, there are particular considerations in this group related to cardiac anatomy and prior surgical repair. Some arrhythmias are intrinsic to the cardiac maldevelopment itself, but most are secondary to surgical scars and the chronic hemodynamic burden conferred by the disordered anatomy.",
"   </p>",
"   <p>",
"    This review will focus on the management of these arrhythmias (",
"    <a class=\"graphic graphic_table graphicRef64292 \" href=\"UTD.htm?42/23/43387\">",
"     table 1",
"    </a>",
"    ), which generally involves a comprehensive multidisciplinary approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181202953\">",
"    <span class=\"h1\">",
"     PREVALENCE AND INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excluding bicuspid aortic valvulopathy, around one percent of live births have some element of CHD (",
"    <a class=\"graphic graphic_table graphicRef78627 \" href=\"UTD.htm?17/43/18107\">",
"     table 2",
"    </a>",
"    ). Minor racial differences in the incidence appear to be the case in the United States, and international variation is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/8\">",
"     8",
"    </a>",
"    ]. Of these, about 45 percent present with milder forms of disease, such as atrial septal defects (ASD) and ventricular septal defects (VSD), somewhat less frequency of moderate forms of congenital heart disease such as tetralogy of Fallot, and the remainder have more complex physiology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/9\">",
"     9",
"    </a>",
"    ]. The epidemiology of congenital heart disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H2707568#H2707568\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The abnormal hemodynamics associated with many cases of CHD creates an arrhythmogenic milieu which increases the likelihood of atrial arrhythmias over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link\">",
"     \"Management and outcome of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=see_link\">",
"     \"Overview of the management of tetralogy of Fallot\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Symptomatic bradyarrhythmias can cause considerable morbidity; pacemaker implantation is required in 3 to 4 percent of patients with Ebstein&rsquo;s anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/10\">",
"     10",
"    </a>",
"    ] or ASD closure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], about 7 percent of Fontan patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and over 80 percent of patients who have undergone atrial switch procedures for d-transposition of the great arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Longitudinal studies suggest that as a whole, atrial tachyarrhythmias afflict at least 20 percent of individuals with CHD over their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/7\">",
"     7",
"    </a>",
"    ]. Approximately half of patients with ASD repair over age 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/12\">",
"     12",
"    </a>",
"    ] and nearly one-third of patients with tetralogy of Fallot develop atrial tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=see_link\">",
"     \"Identification and assessment of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to atrial arrhythmias being associated with more morbidity and higher mortality in patients with CHD, poor functional class, single-ventricle, pulmonary hypertension, and valvular heart disease are all independently associated with a higher risk of death in the patients with atrial arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial arrhythmias are seen in up to half of patients with more complex repairs such as the Fontan operation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. These high rates of atrial arrhythmias have led to the development of novel approaches to Fontan surgery leading to the advent of extracardiac conduit bypass in an effort to reduce the arrhythmic milieu [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. These more recent procedures, however, potentially exclude access to the right heart for conventional transvenous pacemaker lead placement. In addition, atrial tissue that is proving a source of arrhythmia may also be made inaccessible for ablation therapy. Furthermore, permanent pacing may involve a more invasive epicardial pacing system via a thoracotomy or effective ablation of the arrhythmic substrate may be prevented [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H181203142\">",
"     'Permanent pacemaker implantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The frequency of congenital heart disease as a cause of atrial arrhythmias in the fetal heart is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181202960\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardia can be inherent to the congenital anomaly, such as abnormalities or displacement of the sinus node or atrioventricular (AV) node in the heterotaxy (isomerism) syndromes, L-transposition of great arteries, or AV septal defects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, bradycardia is more commonly seen secondary to iatrogenic disruption of these structures and can occur in both the early postoperative period or later due to fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/14,15,24-26\">",
"     14,15,24-26",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef64292 \" href=\"UTD.htm?42/23/43387\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link\">",
"     \"Bradycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tachycardias are most commonly reentrant and have areas of fibrosis near patches or suture lines as their underlying substrate. In addition, cellular injury from longstanding hypoxia and atrial stretch conceivably also engenders inhomogeneity in myocardial refractoriness and hence adds to the arrhythmogenic milieu [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/27\">",
"     27",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef64292 \" href=\"UTD.htm?42/23/43387\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=see_link\">",
"     \"Approach to the child with tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181202968\">",
"    <span class=\"h2\">",
"     Bradycardias",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181202976\">",
"    <span class=\"h3\">",
"     Congenital sinus node dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus venosus atrial septal defects (ASD) (occurring in the septum between the superior vena cava and right-sided pulmonary veins) account for around 5 to 10 percent of all ASDs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Due to the location of this defect, congenital sinus node dysfunction is not infrequently found [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/30\">",
"     30",
"    </a>",
"    ]. This is also the case in the more rare syndromes that involve the heterotaxy syndromes or juxtaposed atrial appendages [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\", section on 'Sinus venosus ASD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604936099\">",
"    <span class=\"h3\">",
"     Acquired sinus node dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any procedure involving atriotomy and cannulation for cardiopulmonary bypass potential risks injury to the sinus node by virtue of its location. More extensive congenital operations involving extensive atrial repair pose additional risk to the sinus node. These include the",
"    <span class=\"nowrap\">",
"     Mustard/Senning,",
"    </span>",
"    Glenn, Fontan and Ebstein&rsquo;s repairs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/14,15,24,32\">",
"     14,15,24,32",
"    </a>",
"    ]. Patients may present with an overt loss of sinus rhythm or a poor chronotropic response to exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: Specific lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181202983\">",
"    <span class=\"h3\">",
"     Congenital AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The atrioventricular (AV) node is a right atrial structure, whereas the His bundle, the electrical continuation of the AV node, is a right ventricular structure. Disorders of misalignment of these two contiguous chambers frequently result in interruption of AV conduction. These anomalies include congenitally corrected transposition of the great arteries (ccTGA, a.k.a. L-TGA), large atrioventricular primum ASDs, and large AV septal defects (AV canal defects) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/23,33\">",
"     23,33",
"    </a>",
"    ]. These malformations can result in either congenital heart block or progressive AV conduction disease, which is seen in around 20 percent of unoperated ccTGA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/34\">",
"     34",
"    </a>",
"    ] and around 5 percent of unoperated primum ASDs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=see_link&amp;anchor=H23#H23\">",
"     \"Pregnancy in women with congenital heart disease: Specific lesions\", section on 'Congenitally corrected transposition of the great arteries'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Primum defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181202997\">",
"    <span class=\"h3\">",
"     Acquired AV node dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical trauma in the region of the atrioventricular conduction axis occurs most commonly with operations that involve this region, such as ventricular septal defect repair, left ventricular outflow tract resection or atrioventricular valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203004\">",
"    <span class=\"h2\">",
"     Tachycardias",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203019\">",
"    <span class=\"h3\">",
"     Intraatrial reentrant tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial scars in repaired CHD patients make intraatrial reentrant tachycardia (IART) the most common form of atrial tachyarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/32\">",
"     32",
"    </a>",
"    ] in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9368?source=see_link\">",
"     \"Intraatrial reentrant tachycardia\"",
"    </a>",
"    .) Mechanistically, IART is similar to atrial flutter, with macro-reentrant circuits.",
"   </p>",
"   <p>",
"    Found primarily in patients where the atrial tissue is most damaged through chronic stretch or extensive atrial scars, these circuits usually develop many years after the original operative intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Older-style intracardiac Fontan repairs, which utilize atrial tissue and",
"    <span class=\"nowrap\">",
"     Mustard/Senning",
"    </span>",
"    procedures, are most commonly associated with this arrhythmia. They can occur also with simple atriotomy scars (",
"    <a class=\"graphic graphic_figure graphicRef75779 \" href=\"UTD.htm?36/16/37125\">",
"     figure 1",
"    </a>",
"    ). Concomitant sinus node dysfunction and older age at first surgical repair also appear to increase the incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/14\">",
"     14",
"    </a>",
"    ]. The atrial rate may vary between 150 and 250 beats per minute; in the presence of preserved AV nodal function, the ensuing ventricular response may be 1:1, leading to rapid clinical deterioration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203026\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary venous origins of atrial fibrillation in CHD do not likely differ markedly from acquired heart disease, although this remains to be fully characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/38\">",
"     38",
"    </a>",
"    ]. Left heart lesions with subsequent left atrial hemodynamic overload are most commonly associated with this rhythm abnormality. Lesions involving the left ventricular outflow tract or mitral valve along with single ventricle physiology with left ventricular predominance remain more common offenders and serve as good examples of the underlying pathophysiology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H2#H2\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'Anatomic origin of AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203033\">",
"    <span class=\"h3\">",
"     Ectopic/focal atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise etiology and prevalence of this arrhythmia in CHD is less clear, and there remains debate as to whether this is an automatic or triggered rhythm, or a combination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link\">",
"     \"Focal atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is far less common than intraatrial reentrant tachycardia (IART), and appears to be more prevalent in children than in adults with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/40\">",
"     40",
"    </a>",
"    ]. It may originate in the Fontan circuit, from the atrial appendages, or adjacent to the pulmonary veins. On the surface electrocardiogram (ECG) this arrhythmia can be identified by the unusual p-wave axis and warm-up of rate. Catheter ablation of the focus, however, is associated with much higher rates of success than IART, and provides an excellent chance of cure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203040\">",
"    <span class=\"h3\">",
"     Twin AV nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplication of the atrioventricular (AV) node and His bundles unusually occurs in the context of single ventricle anatomy and is a very rare cause of congenital atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203047\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203055\">",
"    <span class=\"h2\">",
"     Cardiac referral and further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management and treatment of these patients are often much more complex than more typical arrhythmia patients. Therefore, these patients should be referred to centers that routinely follow this congenital heart population, as recommended in the 2008 American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology guidelines for the management of CHD, [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/43\">",
"     43",
"    </a>",
"    ]. Atrial arrhythmias can be a harbinger of underlying hemodynamic deterioration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203063\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough surgical history, including information including operative reports, is necessary. This information is critical not only in the diagnostic work-up of the atrial arrhythmia, but also in identifying whether venous access for catheters or permanent pacing is feasible. Similarly, during pacing or ablation procedures, inadvertent injury to the AV conduction system may occur. In these instances it is critically necessary to know whether a route to rapidly pace the ventricle endocardially is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203071\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general examination is important to identify evidence for concomitant hemodynamic compromise, which may be integral to the arrhythmia development. For example, the presence of peripheral edema, ascites and an enlarged liver might identify right heart failure from Fontan failure, and revision of this conduit may prove to be the primary intervention for worsening atrial arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203079\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The twelve-lead electrocardiogram (ECG) is instrumental in clarifying the underlying rhythm disturbance, yet can frequently be misleading in CHD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients with intraatrial reentrant tachycardia (IART) often have slower atrial rates with discrete p-waves and an isoelectric interval (as opposed to typical cavo-tricuspid isthmus dependent flutter). This rhythm is occasionally mistaken for sinus tachycardia as the p-wave can be buried in the preceding QRS complex or in the setting of 1:1 conduction through a healthy atrioventricular (AV) node (",
"    <a class=\"graphic graphic_waveform graphicRef52478 \" href=\"UTD.htm?43/25/44440\">",
"     waveform 1",
"    </a>",
"    ). Patients who have undergone modified maze surgeries often have very little evidence of atrial activity on the ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\", section on 'Maze operation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An underlying IART may be missed in this instance and running a longer rhythm strip can be helpful to identify grouped beating occurring in the context of variable AV block. The T wave should also be scrutinized for any sharp deflections not usually associated with repolarization, and hence indicative of atrial depolarization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203087\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transthoracic echocardiographic is invaluable in identifying structural and hemodynamic cardiac disorders that may have precipitated the rhythm disturbance. Conduit or valvular dysfunction may lead to secondary effects on the atrial muscle and thus a pediatric or adult CHD specialist should interpret the echocardiograms in these patients. The echo-Doppler examination may also provide the first clue to an atrial rhythm disturbance or demonstrate reduction in ventricular function from tachycardia. Advances in prenatal diagnosis have allowed preemptive identifications of cardiac anomalies, and this should be considered in fetuses at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=see_link\">",
"     \"Prenatal sonographic diagnosis of fetal cardiac anomalies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203095\">",
"    <span class=\"h2\">",
"     Ambulatory ECG/Holter monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty-four hour Holter recordings can be crucial in identifying the underlying rhythm abnormality when the patient&rsquo;s ECG is unrevealing and there is a history of presyncope, syncope or palpitations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, this can also be a useful adjunctive investigation when chronotropic incompetence is suspected, due to underlying sinus, AV node or medication-related bradycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203103\">",
"    <span class=\"h2\">",
"     Event monitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The event monitor is used to identify the etiology of short-lived symptoms that cannot be characterized by the ECG or Holter recordings. One to three-month periods of transient cardiac event monitors or looping recorders are frequently employed diagnostically, and implantable loop recorders can be considered for persistent symptoms, if not delineated using other noninvasive diagnostic approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203111\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exertional symptoms can be evaluated with either treadmill or bicycle stress tests. Catecholaminergic surges that develop during maximal effort can precipitate arrhythmias by influencing conduction velocity and refractoriness. In addition, faster atrioventricular node function during exercise may allow 1:1 conduction in the context of a previously undiagnosed atrial tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203119\">",
"    <span class=\"h2\">",
"     Electrophysiology study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrophysiology study (EPS) is rarely used to evaluate atrial bradyarrhythmia. However, patients who have undergone extensive atrial surgery, such as right reduction atrioplasty for Ebstein anomaly or modified maze operations, may develop areas of substantial intraatrial block. Thus, identification of this phenomenon can aid in identifying optimal lead position within the diseased atrium. &nbsp;",
"   </p>",
"   <p>",
"    Atrial tachyarrhythmias more frequently require an EPS, as an ablation procedure is often considered early in their management, especially for intraatrial reentrant tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=see_link\">",
"     \"Overview of invasive cardiac electrophysiology studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203127\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203135\">",
"    <span class=\"h2\">",
"     Acute termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;For any atrial tachyarrhythmia that is associated with hemodynamic instability, synchronized direct current (DC) cardioversion should be utilized without delay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DC cardioversion can also be reserved for the initial management of hemodynamically stable yet symptomatic arrhythmias if a more definitive strategy has not yet been chosen, and the patient has fairly infrequent episodes. In this context, transesophageal echocardiography (TEE) to identify intracardiac clot is strongly recommended, especially in Fontan circulations, and regardless of the anticoagulation status. The classical Fontan often promotes sluggish blood flow and atrial thrombus formation. Dissemination of thrombus into the pulmonary bed through DC cardioversion can be fatal in Fontan patients. Cardioversion in the patient with congenital heart disease with appropriate anticoagulation, however, is proven to be safe and effective and should not be with-held [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic bradyarrhythmias may require acute temporary pacing, and knowledge of intracardiac and vena caval anatomy is critical. Anticoagulation is recommended for any CHD patient with an intracardiac shunt receiving a pacemaker to avoid systemic thromboembolism from the pacing lead, until a permanent epicardial system can be placed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=see_link\">",
"     \"Temporary cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203142\">",
"    <span class=\"h2\">",
"     Permanent pacemaker implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the indications for permanent pacing in CHD (",
"    <a class=\"graphic graphic_table graphicRef54980 \" href=\"UTD.htm?17/27/17853\">",
"     table 3",
"    </a>",
"    ) are similar to those in acquired heart disease. All symptomatic sinus or atrioventricular node disease requires pacemaker intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several considerations do exist for pacemaker implantation in patients with CHD. Lead access complications exist in patients with CHD, and a detailed surgical history is vital, often with adjunctive venography or TEE guidance. In complex CHD patients with prior operative intervention in whom surgical reports are not available and urgent pacemaker placement is needed, imaging of venous anatomy with computerized tomography, magnetic resonance imaging or venography should be performed.",
"   </p>",
"   <p>",
"    Consideration needs to be given to epicardial pacemaker placement if a residual interventricular shunt exists [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. While coronary sinus lead placement is utilized with increasing frequency for ventricular pacing when the tricuspid valve cannot be crossed, this has not been prospectively evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203150\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiarrhythmic drugs (AADs) remain a cornerstone in the management of atrial arrhythmias in CHD patients. Most AADs should not be routinely used in this patient group with organic heart disease, vulnerable myocardium through systemic hypoxia and the reentrant substrate of prior scars due to the presence of significant side effects. The risks of proarrhythmia resulting from antiarrhythmic therapy are increased in this patient population and the risks and benefits of a particular antiarrhythmic agent need to be considered carefully [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=see_link\">",
"     \"Arrhythmia management for the primary care clinician\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most effective drug currently remains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , although significant side effects may be problematic and lead to noncompliance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    .) Long-term use of amiodarone requires close monitoring of pulmonary and hepatic function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/56\">",
"     56",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    may be the safest alternate AADs in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/57\">",
"     57",
"    </a>",
"    ], while class Ic agents are avoided in the context of hypertrophy or ventricular scar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link\">",
"     \"Therapeutic use of dofetilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203157\">",
"    <span class=\"h2\">",
"     Ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency catheter ablation (RFA) is now utilized early in the course of many adult patients with atrial tachyarrhythmias, particularly atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RFA can be considered in patients with CHD, such as those with intraatrial reentrant tachycardia, but should be referred to experienced centers. Although early success rates are excellent even in the most complex defects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/58\">",
"     58",
"    </a>",
"    ], long-term recurrence rates remain suboptimal, especially when multiple circuits coexist and atrial scars are abundant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/59\">",
"     59",
"    </a>",
"    ]. The reentrant circuit can often be modified sufficiently to reduce symptomatic recurrence and improve antiarrhythmic drug therapy or pacing efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Older age at time of ablation and complexity of the atrial repair (Fontan or atrial-switch) both predict worse procedural success [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/63\">",
"     63",
"    </a>",
"    ]. It is also important to recognize that RFA in this context is also often associated with unmasking underlying sinus node dysfunction, and not infrequently permanent pacing is required [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/63\">",
"     63",
"    </a>",
"    ]. For this reason we recommend discussing this antecedently with patients.",
"   </p>",
"   <p>",
"    Atrial fibrillation ablation with pulmonary vein isolation can be considered in symptomatic patients refractory to drug therapy, yet no outcome data exist in CHD patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203164\">",
"    <span class=\"h2\">",
"     Antitachycardia devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, antitachycardia pacemakers were used to treat reentrant SVTs in this patient population. However, over time it has been recognized that their long-term effectiveness is low. Because of this, implantation of any type of a pacemaker should only be considered in patients with symptomatic bradycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other clear indications for pacing due to an increased risk of AF block. In patients with both bradycardia and atrial arrhythmias, high-rate atrial pacing may slightly reduce the risk of recurrence. &nbsp;",
"   </p>",
"   <p>",
"    Generally, this approach is reserved for patients who also present with bradycardia, and has been shown to reduce symptomatic exacerbations in this particular tachy-brady group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. This can be assessed at the time of an electrophysiology study and may also be utilized in conjunction with AADs. Newer devices have sophisticated antitachycardia capability that their use as an adjunct to the maze procedure, maze-like ablation approaches, and antiarrhythmic therapy is being increasingly utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203171\">",
"    <span class=\"h2\">",
"     Maze surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;CHD patients undergoing operative repair of a residual or new cardiac defect should be considered for maze surgery if there is a background of atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/68\">",
"     68",
"    </a>",
"    ]. Cut-and-sew techniques, which were relied on in the past, have now been replaced with alternative ablation strategies. No data currently exist on preemptive maze surgery in CHD patients at high risk for, but without, prior documented arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\", section on 'Maze operation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203179\">",
"    <span class=\"h2\">",
"     Anticoagulation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation therapy should be considered in CHD patients as soon as an atrial rhythm disturbance is identified. Patients with Fontan circulations or reduced right ventricular function have low flow states in the right heart and are at high risk of thrombus formation within the atria. Patients with repaired atrial septal defects also appear to be at considerable risk for thromboembolic complications in the setting of atrial arrhythmias, accounting for around one-fifth of late deaths in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/12\">",
"     12",
"    </a>",
"    ]. The use of conventional thromboembolic risk-assessment scores, such as CHADS2, has not been evaluated in these patient groups and likely is inappropriate. Although the newer oral anticoagulant agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    have not been specifically studied in CHD patients, it is reasonable to consider them in patients who have presented difficulties tolerating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203193\">",
"    <span class=\"h1\">",
"     SPECIFIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203202\">",
"    <span class=\"h2\">",
"     Accessory pathways and Ebstein&rsquo;s anomaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ebstein&rsquo;s anomaly encompasses a wide spectrum of maldevelopment of the tricuspid valve, massive right atrial dilatation and underdeveloped right ventricular function. Accessory pathways are present in at least one-fifth of patients with Ebstein&rsquo;s anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/69\">",
"     69",
"    </a>",
"    ], are almost always right-sided (or concordant with the side of Ebstein valve in case of transposition) and may be multiple [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Catheter ablation is highly effective in eliminating these accessory pathways and should be considered as first-line therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial arrhythmias that conduct rapidly to the ventricle via the accessory pathway may cause hemodynamic deterioration, syncope and even death. The presence of an accessory pathway in any patient has also been strongly linked to the development of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/74\">",
"     74",
"    </a>",
"    ]. The ablation of the pathway often results in termination of the atrial rhythm abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/75\">",
"     75",
"    </a>",
"    ]. However, macro-reentrant atrial flutters in the context of postoperative CHD will not be ameliorated by accessory pathway ablation. More importantly, ablation of accessory pathways in these patients is critical as preexcited atrial fibrillation or atrial flutter can be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/74\">",
"     74",
"    </a>",
"    ]. Therefore, the approach to these patients should be to initially remove the accessory pathway so that the risk of sudden death has decreased significantly and then address which atrial arrhythmias remain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203209\">",
"    <span class=\"h2\">",
"     ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial septal defect (ASD) is one of the most common congenital cardiac anomalies, and is associated with a high incidence of atrial arrhythmias, which increase in frequency as these patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link\">",
"     \"Management of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The later in life the ASD is repaired, the more likely atrial arrhythmias are to develop. Closure does not mitigate the development of this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, significant thromboembolic complications have been observed in patients who had ASD closure performed at age 24 years of age or older, affecting around 22 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/12\">",
"     12",
"    </a>",
"    ]. For this reason, anticoagulation should be mandatory if this rhythm abnormality occurs, and should be actively sought using Holter monitoring. Intraatrial reentrant tachycardia circuits around a patch or suture line frequently underlie the abnormality and ablative therapy can be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H181203157\">",
"     'Ablation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203224\">",
"    <span class=\"h2\">",
"     Prior maze",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modified maze operations are a common, safe and highly effective surgical method of restoring sinus rhythm in patients with CHD and atrial",
"    <span class=\"nowrap\">",
"     fibrillation/flutter.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These interventions, which are often performed at the time of CHD operations, can be effective in preventing atrial arrhythmia recurrence approximately 90 and 80 percent at 1 and 10 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/77\">",
"     77",
"    </a>",
"    ]. Patients with prior maze procedures can develop breakthrough atrial tachyarrhythmias at points of incomplete atrial block; this is less common with traditional cut-and-sew maze procedures than with open surgical radio-frequency or cryotherapy approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The maze procedure is not free of complications; the extensive transmural lesions not only potentially interfere with sinus and intraatrial conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/79\">",
"     79",
"    </a>",
"    ], but likely also disrupt atrial innervation. Sinus node dysfunction, atrial bradyarrhythmias and tachyarrhythmias and inappropriate heart rate responses to activity are not uncommon sequelae and pacemaker implantation is frequently necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/80\">",
"     80",
"    </a>",
"    ]. New atrial tachyarrhythmias can develop around maze lesions, and ablation of intraatrial reentrant tachycardia in this setting can be difficult with no reports available on long-term efficacy. Frequently antiarrhythmic drug therapy is relied on in this context, and atrial antitachycardia pacemakers can be of added utility [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203239\">",
"    <span class=\"h2\">",
"     Tetralogy of Fallot",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradyarrhythmias requiring permanent pacing in patients with tetralogy of Fallot are uncommon. However, atrial tachyarrhythmias are a frequent cause of morbidity and may be seen in up to 25 percent of TOF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/16\">",
"     16",
"    </a>",
"    ]. There are conflicting data as to whether this is primarily driven by volume overload of the right-sided chambers with right atrial enlargement versus concomitant left-atrial enlargement or residual ventricular septal defect [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/16,82\">",
"     16,82",
"    </a>",
"    ], but presents as symptomatic episodes in up to 40 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=see_link\">",
"     \"Overview of the management of tetralogy of Fallot\"",
"    </a>",
"    .) The prevalence of atrial fibrillation markedly increases after 45 years of age in this group and in those with reduced left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203246\">",
"    <span class=\"h2\">",
"     Fontan procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fontan procedures that utilize right atrial tissue as part of the conduit are frequently associated with to the development of late atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/84\">",
"     84",
"    </a>",
"    ]. The development of an automatic tachycardia in this context should raise suspicion for an underlying hemodynamic issue, but often this mechanism can only be definitively determined with cardiac catheterization and electrophysiological study. A detailed look at potential obstruction in the circuit",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AV valve regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/32\">",
"     32",
"    </a>",
"    ] should be undertaken. Conversion to an extracardiac conduit or total cavopulmonary connection may provide hemodynamic relief and improve the arrhythmia burden [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injury to the sinus node is also common [",
"    <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=see_link\">",
"       \"Patient information: Heart block in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20369?source=see_link\">",
"       \"Patient information: Heart block in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181203253\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial arrhythmias are common in congenital heart disease (CHD) and, in addition to being a major cause of morbidity, can often be symptomatic of underlying hemodynamic deterioration. The abnormal hemodynamics associated with many cases of CHD creates an arrhythmogenic milieu, which increases the likelihood of atrial arrhythmias over time. (See",
"      <a class=\"local\" href=\"#H181202953\">",
"       'Prevalence and incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be referred to centers that routinely follow this population, as recommended in the 2008 American Heart",
"      <span class=\"nowrap\">",
"       Association/American",
"      </span>",
"      College of Cardiology guidelines for the management of CHD, [",
"      <a class=\"abstract\" href=\"UTD.htm?16/52/17226/abstract/43\">",
"       43",
"      </a>",
"      ]. Atrial arrhythmias can be a harbinger of underlying hemodynamic deterioration. (See",
"      <a class=\"local\" href=\"#H181203047\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bradycardia can be inherent to the congenital anomaly, such as displacement of the sinus node or atrioventricular (AV) node in the isomerism syndromes or with atrioventricular septal defects respectively. However, bradycardia is more commonly seen secondary to iatrogenic disruption of these structures and can occur in both the early postoperative period or later due to fibrosis (See",
"      <a class=\"local\" href=\"#H181202968\">",
"       'Bradycardias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrial tachyarrhythmias afflict at least 20 percent of individuals with CHD over their lifetime. (See",
"      <a class=\"local\" href=\"#H181202953\">",
"       'Prevalence and incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For any atrial tachyarrhythmia that is associated with hemodynamic instability, synchronized direct current (DC) cardioversion should be utilized without delay. (See",
"      <a class=\"local\" href=\"#H181203127\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the indications for permanent pacing in CHD are similar to those in acquired heart disease. All symptomatic sinus or atrioventricular node disease requires pacemaker intervention. (See",
"      <a class=\"local\" href=\"#H181203142\">",
"       'Permanent pacemaker implantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/1\">",
"      Marelli AJ, Mackie AS, Ionescu-Ittu R, et al. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007; 115:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/2\">",
"      Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults. Second of two parts. N Engl J Med 2000; 342:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/3\">",
"      Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults. First of two parts. N Engl J Med 2000; 342:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/4\">",
"      Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/5\">",
"      Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/6\">",
"      Kanter RJ, Garson A Jr. Atrial arrhythmias during chronic follow-up of surgery for complex congenital heart disease. Pacing Clin Electrophysiol 1997; 20:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/7\">",
"      Bouchardy J, Therrien J, Pilote L, et al. Atrial arrhythmias in adults with congenital heart disease. Circulation 2009; 120:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/8\">",
"      Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics 2001; 107:E32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/9\">",
"      Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation 2007; 115:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/10\">",
"      Allen MR, Hayes DL, Warnes CA, Danielson GK. Permanent pacing in Ebstein's anomaly. Pacing Clin Electrophysiol 1997; 20:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/11\">",
"      Meijboom F, Hess J, Szatmari A, et al. Long-term follow-up (9 to 20 years) after surgical closure of atrial septal defect at a young age. Am J Cardiol 1993; 72:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/12\">",
"      Murphy JG, Gersh BJ, McGoon MD, et al. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N Engl J Med 1990; 323:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/13\">",
"      Cohen MI, Wernovsky G, Vetter VL, et al. Sinus node function after a systematically staged Fontan procedure. Circulation 1998; 98:II352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/14\">",
"      Fishberger SB, Wernovsky G, Gentles TL, et al. Factors that influence the development of atrial flutter after the Fontan operation. J Thorac Cardiovasc Surg 1997; 113:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/15\">",
"      Flinn CJ, Wolff GS, Dick M 2nd, et al. Cardiac rhythm after the Mustard operation for complete transposition of the great arteries. N Engl J Med 1984; 310:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/16\">",
"      Roos-Hesselink J, Perlroth MG, McGhie J, Spitaels S. Atrial arrhythmias in adults after repair of tetralogy of Fallot. Correlations with clinical, exercise, and echocardiographic findings. Circulation 1995; 91:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/17\">",
"      Yap SC, Harris L, Chauhan VS, et al. Identifying high risk in adults with congenital heart disease and atrial arrhythmias. Am J Cardiol 2011; 108:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/18\">",
"      Stephenson EA, Lu M, Berul CI, et al. Arrhythmias in a contemporary fontan cohort: prevalence and clinical associations in a multicenter cross-sectional study. J Am Coll Cardiol 2010; 56:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/19\">",
"      Cecchin F, Johnsrude CL, Perry JC, Friedman RA. Effect of age and surgical technique on symptomatic arrhythmias after the Fontan procedure. Am J Cardiol 1995; 76:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/20\">",
"      Stamm C, Friehs I, Mayer JE Jr, et al. Long-term results of the lateral tunnel Fontan operation. J Thorac Cardiovasc Surg 2001; 121:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/21\">",
"      El Yaman MM, Asirvatham SJ, Kapa S, et al. Methods to access the surgically excluded cavotricuspid isthmus for complete ablation of typical atrial flutter in patients with congenital heart defects. Heart Rhythm 2009; 6:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/22\">",
"      Momma K, Takao A, Shibata T. Characteristics and natural history of abnormal atrial rhythms in left isomerism. Am J Cardiol 1990; 65:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/23\">",
"      Anderson RH, Ho SY. The morphology of the specialized atrioventricular junctional area: the evolution of understanding. Pacing Clin Electrophysiol 2002; 25:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/24\">",
"      Manning PB, Mayer JE Jr, Wernovsky G, et al. Staged operation to Fontan increases the incidence of sinoatrial node dysfunction. J Thorac Cardiovasc Surg 1996; 111:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/25\">",
"      Weindling SN, Saul JP, Gamble WJ, et al. Duration of complete atrioventricular block after congenital heart disease surgery. Am J Cardiol 1998; 82:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/26\">",
"      Bruckheimer E, Berul CI, Kopf GS, et al. Late recovery of surgically-induced atrioventricular block in patients with congenital heart disease. J Interv Card Electrophysiol 2002; 6:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/27\">",
"      Walsh EP. Interventional electrophysiology in patients with congenital heart disease. Circulation 2007; 115:3224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/28\">",
"      Oliver JM, Gallego P, Gonzalez A, et al. Sinus venosus syndrome: atrial septal defect or anomalous venous connection? A multiplane transoesophageal approach. Heart 2002; 88:634.",
"     </a>",
"    </li>",
"    <li>",
"     Peacock, TB. Malformations of the heart. In: On Malformations of the Human Heart: With Original Cases, Peacock, TB (Eds), John Churchill, London 1858. p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/30\">",
"      Attenhofer Jost CH, Connolly HM, Danielson GK, et al. Sinus venosus atrial septal defect: long-term postoperative outcome for 115 patients. Circulation 2005; 112:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/31\">",
"      Anjos RT, Ho SY, Anderson RH. Surgical implications of juxtaposition of the atrial appendages. A review of forty-nine autopsied hearts. J Thorac Cardiovasc Surg 1990; 99:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/32\">",
"      Ghai A, Harris L, Harrison DA, et al. Outcomes of late atrial tachyarrhythmias in adults after the Fontan operation. J Am Coll Cardiol 2001; 37:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/33\">",
"      Anderson RH, Shinebourne EA, Gerlis LM. Criss-cross atrioventricular relationships producing paradoxical atrioventricular concordance or discordance. Their significance to nomenclature of congenital heart disease. Circulation 1974; 50:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/34\">",
"      Connelly MS, Liu PP, Williams WG, et al. Congenitally corrected transposition of the great arteries in the adult: functional status and complications. J Am Coll Cardiol 1996; 27:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/35\">",
"      Campbell M. Natural history of atrial septal defect. Br Heart J 1970; 32:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/36\">",
"      Li W, Somerville J. Atrial flutter in grown-up congenital heart (GUCH) patients. Clinical characteristics of affected population. Int J Cardiol 2000; 75:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/37\">",
"      Wong T, Davlouros PA, Li W, et al. Mechano-electrical interaction late after Fontan operation: relation between P-wave duration and dispersion, right atrial size, and atrial arrhythmias. Circulation 2004; 109:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/38\">",
"      Ha&iuml;ssaguerre M, Ja&iuml;s P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/39\">",
"      Kirsh JA, Walsh EP, Triedman JK. Prevalence of and risk factors for atrial fibrillation and intra-atrial reentrant tachycardia among patients with congenital heart disease. Am J Cardiol 2002; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     Walsh, EP, Walsh, EP, Saul, JP, Triedman, JK. Cardiac arrhythmias in children and young adults with congenital heart disease, Lippincott Williams &amp; Wilkins, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/41\">",
"      Tracy CM, Swartz JF, Fletcher RD, et al. Radiofrequency catheter ablation of ectopic atrial tachycardia using paced activation sequence mapping. J Am Coll Cardiol 1993; 21:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/42\">",
"      Epstein MR, Saul JP, Weindling SN, et al. Atrioventricular reciprocating tachycardia involving twin atrioventricular nodes in patients with complex congenital heart disease. J Cardiovasc Electrophysiol 2001; 12:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/43\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/44\">",
"      Akar JG, Kok LC, Haines DE, et al. Coexistence of type I atrial flutter and intra-atrial re-entrant tachycardia in patients with surgically corrected congenital heart disease. J Am Coll Cardiol 2001; 38:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/45\">",
"      Park HE, Kim KH, Kim KB, et al. Characteristics of P wave in patients with sinus rhythm after maze operation. J Korean Med Sci 2010; 25:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/46\">",
"      Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block. N Engl J Med 1987; 316:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/47\">",
"      Ammash NM, Phillips SD, Hodge DO, et al. Outcome of direct current cardioversion for atrial arrhythmias in adults with congenital heart disease. Int J Cardiol 2012; 154:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/48\">",
"      Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008; 5:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/49\">",
"      Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation 2006; 113:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/50\">",
"      Cohen MI, Bush DM, Vetter VL, et al. Permanent epicardial pacing in pediatric patients: seventeen years of experience and 1200 outpatient visits. Circulation 2001; 103:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/51\">",
"      Odim J, Suckow B, Saedi B, et al. Equivalent performance of epicardial versus endocardial permanent pacing in children: a single institution and manufacturer experience. Ann Thorac Surg 2008; 85:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/52\">",
"      Perry JC, Garson A Jr. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am Heart J 1992; 124:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/53\">",
"      Pfammatter JP, Paul T, Lehmann C, Kallfelz HC. Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol 1995; 26:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/54\">",
"      Anastasiou-Nana MI, Anderson JL, Stewart JR, et al. Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect. Am Heart J 1987; 113:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/55\">",
"      Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation 1999; 100:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/56\">",
"      Wells R, Khairy P, Harris L, et al. Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study. Pacing Clin Electrophysiol 2009; 32:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/57\">",
"      Miyazaki A, Ohuchi H, Kurosaki K, et al. Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. Circ J 2008; 72:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/58\">",
"      Kanter RJ, Papagiannis J, Carboni MP, et al. Radiofrequency catheter ablation of supraventricular tachycardia substrates after mustard and senning operations for d-transposition of the great arteries. J Am Coll Cardiol 2000; 35:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/59\">",
"      de Groot NM, Atary JZ, Blom NA, Schalij MJ. Long-term outcome after ablative therapy of postoperative atrial tachyarrhythmia in patients with congenital heart disease and characteristics of atrial tachyarrhythmia recurrences. Circ Arrhythm Electrophysiol 2010; 3:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/60\">",
"      Triedman JK, Alexander ME, Love BA, et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol 2002; 39:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/61\">",
"      Ja&iuml;s P, Shah DC, Ha&iuml;ssaguerre M, et al. Prospective randomized comparison of irrigated-tip versus conventional-tip catheters for ablation of common flutter. Circulation 2000; 101:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/62\">",
"      Triedman JK, DeLucca JM, Alexander ME, et al. Prospective trial of electroanatomically guided, irrigated catheter ablation of atrial tachycardia in patients with congenital heart disease. Heart Rhythm 2005; 2:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/63\">",
"      Yap SC, Harris L, Silversides CK, et al. Outcome of intra-atrial re-entrant tachycardia catheter ablation in adults with congenital heart disease: negative impact of age and complex atrial surgery. J Am Coll Cardiol 2010; 56:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/64\">",
"      Rhodes LA, Walsh EP, Gamble WJ, et al. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease. Pacing Clin Electrophysiol 1995; 18:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/65\">",
"      Stephenson EA, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol 2003; 92:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/66\">",
"      Funck RC, Boriani G, Manolis AS, et al. The MINERVA study design and rationale: a controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias. Am Heart J 2008; 156:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/67\">",
"      Weber S, Jeron A, Schneider HJ, Muders F. Efficacy of patient activated antitachycardia pacing therapy using the Medtronic AT500 pacemaker. Europace 2006; 8:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/68\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/69\">",
"      Attenhofer Jost CH, Connolly HM, Dearani JA, et al. Ebstein's anomaly. Circulation 2007; 115:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/70\">",
"      Ho SY, Goltz D, McCarthy K, et al. The atrioventricular junctions in Ebstein malformation. Heart 2000; 83:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/71\">",
"      Smith WM, Gallagher JJ, Kerr CR, et al. The electrophysiologic basis and management of symptomatic recurrent tachycardia in patients with Ebstein's anomaly of the tricuspid valve. Am J Cardiol 1982; 49:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/72\">",
"      Hebe J. Ebstein's anomaly in adults. Arrhythmias: diagnosis and therapeutic approach. Thorac Cardiovasc Surg 2000; 48:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/73\">",
"      Attie F, Rosas M, Rijlaarsdam M, et al. The adult patient with Ebstein anomaly. Outcome in 72 unoperated patients. Medicine (Baltimore) 2000; 79:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/74\">",
"      Chen PS, Pressley JC, Tang AS, et al. New observations on atrial fibrillation before and after surgical treatment in patients with the Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1992; 19:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/75\">",
"      Campbell RW, Smith RA, Gallagher JJ, et al. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol 1977; 40:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/76\">",
"      Kalman JM, VanHare GF, Olgin JE, et al. Ablation of 'incisional' reentrant atrial tachycardia complicating surgery for congenital heart disease. Use of entrainment to define a critical isthmus of conduction. Circulation 1996; 93:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/77\">",
"      Mavroudis C, Deal BJ, Backer CL, Tsao S. Arrhythmia surgery in patients with and without congenital heart disease. Ann Thorac Surg 2008; 86:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/78\">",
"      Stulak JM, Dearani JA, Sundt TM 3rd, et al. Superiority of cut-and-sew technique for the Cox maze procedure: comparison with radiofrequency ablation. J Thorac Cardiovasc Surg 2007; 133:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/79\">",
"      Pasic M, Musci M, Siniawski H, et al. The Cox maze iii procedure: parallel normalization of sinus node dysfunction, improvement of atrial function, and recovery of the cardiac autonomic nervous system. J Thorac Cardiovasc Surg 1999; 118:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/80\">",
"      Izumoto H, Kawazoe K, Kitahara H, Kamata J. Operative results after the Cox/maze procedure combined with a mitral valve operation. Ann Thorac Surg 1998; 66:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/81\">",
"      Drago F, Silvetti MS, Grutter G, De Santis A. Long term management of atrial arrhythmias in young patients with sick sinus syndrome undergoing early operation to correct congenital heart disease. Europace 2006; 8:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/82\">",
"      Rosianu S, Paprika D, Osztheimer I, et al. Echocardiographic evaluation of patients with undocumented arrhythmias occurring in adults late after repair of tetralogy of Fallot. Eur J Echocardiogr 2009; 10:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/83\">",
"      Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. Circulation 2010; 122:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/84\">",
"      Gelatt M, Hamilton RM, McCrindle BW, et al. Risk factors for atrial tachyarrhythmias after the Fontan operation. J Am Coll Cardiol 1994; 24:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/85\">",
"      Mavroudis C, Backer CL, Deal BJ. Late reoperations for Fontan patients: state of the art invited review. Eur J Cardiothorac Surg 2008; 34:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/52/17226/abstract/86\">",
"      Takahashi K, Cecchin F, Fortescue E, et al. Permanent atrial pacing lead implant route after Fontan operation. Pacing Clin Electrophysiol 2009; 32:779.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13599 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-B6EAAB5947-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17226=[""].join("\n");
var outline_f16_52_17226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H181203253\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181202946\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181202953\">",
"      PREVALENCE AND INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181202960\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181202968\">",
"      Bradycardias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181202976\">",
"      - Congenital sinus node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H604936099\">",
"      - Acquired sinus node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181202983\">",
"      - Congenital AV block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181202997\">",
"      - Acquired AV node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203004\">",
"      Tachycardias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181203019\">",
"      - Intraatrial reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181203026\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181203033\">",
"      - Ectopic/focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181203040\">",
"      - Twin AV nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181203047\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203055\">",
"      Cardiac referral and further evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203063\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203071\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203079\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203087\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203095\">",
"      Ambulatory ECG/Holter monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203103\">",
"      Event monitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203111\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203119\">",
"      Electrophysiology study",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181203127\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203135\">",
"      Acute termination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203142\">",
"      Permanent pacemaker implantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203150\">",
"      Antiarrhythmic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203157\">",
"      Ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203164\">",
"      Antitachycardia devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203171\">",
"      Maze surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203179\">",
"      Anticoagulation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181203193\">",
"      SPECIFIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203202\">",
"      Accessory pathways and Ebstein&rsquo;s anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203209\">",
"      ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203224\">",
"      Prior maze",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203239\">",
"      Tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181203246\">",
"      Fontan procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181203253\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/13599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13599|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/16/37125\" title=\"figure 1\">",
"      Atriotomy scars",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/23/43387\" title=\"table 1\">",
"      Etiology of arrhythmias in congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/43/18107\" title=\"table 2\">",
"      Common congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/27/17853\" title=\"table 3\">",
"      ACC AHA HRS congenital HD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13599|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/25/44440\" title=\"waveform 1\">",
"      Intraatrial reentrant tachycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=related_link\">",
"      Approach to the child with tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=related_link\">",
"      Arrhythmia management for the primary care clinician",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=related_link\">",
"      Bradycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=related_link\">",
"      Identification and assessment of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9368?source=related_link\">",
"      Intraatrial reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=related_link\">",
"      Management and outcome of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=related_link\">",
"      Management of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=related_link\">",
"      Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=related_link\">",
"      Overview of the management of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=related_link\">",
"      Patient information: Heart block in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20369?source=related_link\">",
"      Patient information: Heart block in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=related_link\">",
"      Pregnancy in women with congenital heart disease: Specific lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal cardiac anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=related_link\">",
"      Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_52_17227="Acromioclavicular injury grading";
var content_f16_52_17227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acromioclavicular injury classification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Type I",
"       </td>",
"       <td>",
"        Acromioclavicular (AC) ligament sprain; AC joint intact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Type II",
"       </td>",
"       <td>",
"        Acromioclavicular ligament torn, coracoclavicular (CC) ligament intact; AC joint subluxed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Type III",
"       </td>",
"       <td>",
"        AC and CC ligaments torn; complete dislocation of the joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Type IV",
"       </td>",
"       <td>",
"        Complete dislocation with posterior displacement of distal clavicle into or through trapezius muscle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Type V",
"       </td>",
"       <td>",
"        Superior dislocation of the joint of one to three times the normal spacing, increasing the CC ligament distance two to three times normal; disruption of the deltotrapezial fascia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Type VI",
"       </td>",
"       <td>",
"        Complete dislocation with inferior displacement of distal clavicle into a subacromial or subcoracoid position",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17227=[""].join("\n");
var outline_f16_52_17227=null;
var title_f16_52_17228="Major causes of sudden death";
var content_f16_52_17228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of sudden death",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ischemic heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary artery disease with myocardial infarction or angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary artery embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonatherogenic coronary artery disease (arteritis, dissection, congenital coronary artery anomalies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary artery spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nonischemic heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertrophic cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilated cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valvular heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmogenic right ventricular dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pericardial tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myocardial rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        No structural heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary electrical disease (idiopathic ventricular fibrillation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brugada syndrome (right bundle branch block and ST segment elevation in leads V1 to V3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long QT syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preexcitation syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete heart block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial sudden cardiac death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest wall trauma (commotio cordis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noncardiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drowning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pickwickian syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sudden infant death syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17228=[""].join("\n");
var outline_f16_52_17228=null;
var title_f16_52_17229="Pediatric causes metabolic acidosis";
var content_f16_52_17229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric causes of metabolic acidosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Elevated anion gap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Lactic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Hypoperfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cardiac failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Septic shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Mitochondrial disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Inborn error of metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mitochondrial, Encephalomyopathy, Lactic Acidosis and Strokelike Episodes (MELAS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Myoclonus Epilepsy and Ragged-Red Fibers (MERRF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Kearns-Sayre syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Acquired (antiretroviral therapy in HIV patients)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Inborn errors of metabolism (carbohydrate metabolism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fructose 1,6 diphosphatase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Glycogen storage disease 1 (glucose 6 phosphate deficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pyruvate dehydrogenase or carboxylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ketoacidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetic ketoacidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Inborn errors of metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Organic acidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Maple syrup urine disease (branched-chain amino acids)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Propionic acidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Methylmalonic acidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ketothiolase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Multiple carboxylase deficiency (impaired biotin utilization)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fatty acid oxidation defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ingestions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyanide poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ethanol intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metformin poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonsteroidal antiinflammatory drug poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salicylates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Massive rhabdomyolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tumor lysis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Normal anion gap (hyperchloremic metabolic acidosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Loss of HCO3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Gastrointestinal loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic laxative abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Enteric fistulae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ureterosigmoidostomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Renal loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Proximal (Type 2) renal tubular acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Diminished H+ secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal (Type 1) renal tubular acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Early renal failure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17229=[""].join("\n");
var outline_f16_52_17229=null;
var title_f16_52_17230="Acute treatment of moderate asthma in children";
var content_f16_52_17230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Management of moderate asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 427px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Consider IM methylpredisolone or oral dexamethasone if the child vomits prednisone.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Scarfone, MD, FAAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17230=[""].join("\n");
var outline_f16_52_17230=null;
var title_f16_52_17231="NHL rectum Endosc";
var content_f16_52_17231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Non-Hodgkin lymphoma of rectum on endoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the rectum in a 95-year-old patient who presented with weight loss and anemia. The biopsy revealed non Hodgkins lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alfonso Sandoval, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_52_17231=[""].join("\n");
var outline_f16_52_17231=null;
